Detailed information for compound 19331
Basic information
Technical information
- TDR Targets ID: 19331
- Name: 5-[[4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl]m ethyl]-1,3-thiazolidine-2,4-dione
- MW: 356.439 | Formula: C19H20N2O3S
-
H donors: 1
H acceptors: 3
LogP: 3.75
Rotable bonds: 7
Rule of 5 violations (Lipinski): 1 - SMILES: CCc1ccc(nc1)CCOc1ccc(cc1)CC1SC(=O)NC1=O
- InChi: 1S/C19H20N2O3S/c1-2-13-3-6-15(20-12-13)9-10-24-16-7-4-14(5-8-16)11-17-18(22)21-19(23)25-17/h3-8,12,17H,2,9-11H2,1H3,(H,21,22,23)
- InChiKey: HYAFETHFCAUJAY-UHFFFAOYSA-N
Network
Hover on a compound node to display the structore
Synonyms
- Pioglitazona [Inn-Spanish]
- Pioglitazone
- Pioglitazone Hydrochloride
- Pioglitazone [Ban:Inn]
- Pioglitazonum [Inn-Latin]
- 5-[[4-[2-(5-ethyl-2-pyridyl)ethoxy]phenyl]methyl]thiazolidine-2,4-dione
- 5-[4-[2-(5-ethyl-2-pyridyl)ethoxy]benzyl]thiazolidine-2,4-quinone
- 111025-46-8
- 105355-27-9
- C07675
- 5-[4-[2-(5-Ethyl-2-pyridyl)ethoxy]benzyl]thiazolidine-2,4-dione
- 2,4-Thiazolidinedione, 5-((4-(2-(5-ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-
- 5-((4-(2-(5-Ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione
- KBio3_001943
- NCGC00163128-01
- Spectrum3_001002
- BB_SC-4137
- (+/-)-5-[[4-[2-(5-Ethyl-2-pyridinyl)-ethoxy]phenyl]methyl]-2,4-thiazolidinedione
- (+/-)-5-[p-[2-(ethyl-2-pyridyl)ethoxy]benzyl]-2,4-thiazolidinedione
- 2,4-Thiazolidinedione, 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]- (9CI)
- 2,4-Thiazolidinedione, 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-, (+/-)-
- 2,4-thiazolidinedione, 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-
- KBio2_002103
- BSPBio_002723
- KBioSS_002103
- U 72107
- Spectrum_001623
- Spectrum5_002067
- KBioGR_001619
- KBio2_004671
- KBio2_007239
- 5-[[4-[2-(5-Ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-2,4-thiazolidinedione
- nchembio790-comp10
- SPBio_001897
- Spectrum4_001130
- Spectrum5_001480
- Spectrum2_001679
- 5-[[4-[2-[(5-ethyl-2-pyridyl)]ethoxy]phenyl]methyl]thiazolidine- 2,4-dione
- 2,4-Thiazolidinedione, 5-((4-(2-(5-ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-, (+-)-
- HSDB 7322
Targets
Known targets for this compound
Predicted pathogen targets for this compound
By orthology
By sequence similarity to non orthologous known druggable targets
Obtained from network model
Ranking Plot
Putative Targets List
| Species | Potential target | Raw | Global | Species |
|---|---|---|---|---|
| Wolbachia endosymbiont of Brugia malayi | exonuclease III | 0.0023 | 0.0175 | 0.5 |
| Echinococcus granulosus | nuclear receptor 2DBD gamma | 0.004 | 0.0385 | 0.0385 |
| Trypanosoma cruzi | choline/carnitine O-acetyltransferase, putative | 0.002 | 0.0138 | 0.0633 |
| Echinococcus multilocularis | carbonic anhydrase II | 0.0147 | 0.1717 | 0.1717 |
| Mycobacterium leprae | PROBABLE OXIDOREDUCTASE | 0.0038 | 0.0368 | 0.4498 |
| Schistosoma mansoni | nuclear receptor | 0.0019 | 0.0126 | 0.0126 |
| Trichomonas vaginalis | aldo-keto reductase, putative | 0.0038 | 0.0368 | 0.4498 |
| Schistosoma mansoni | amine oxidase | 0.0051 | 0.0519 | 0.0519 |
| Mycobacterium ulcerans | beta-lactamase | 0.0071 | 0.0779 | 0.0856 |
| Loa Loa (eye worm) | carbonic anhydrase 3 | 0.0147 | 0.1717 | 0.4572 |
| Loa Loa (eye worm) | hypothetical protein | 0.0069 | 0.0743 | 0.198 |
| Trichomonas vaginalis | ABC transporter, putative | 0.0025 | 0.0209 | 0.2381 |
| Echinococcus multilocularis | microtubule associated protein 2 | 0.0697 | 0.8525 | 0.8525 |
| Echinococcus multilocularis | aldo keto reductase family 1, member B4 | 0.0038 | 0.0368 | 0.0368 |
| Echinococcus multilocularis | Nuclear hormone receptor HR96 | 0.0019 | 0.0126 | 0.0126 |
| Trichomonas vaginalis | lipid A export ATP-binding/permease protein msba, putative | 0.0025 | 0.0209 | 0.2381 |
| Trypanosoma brucei | aldo-keto reductase, putative | 0.0038 | 0.0368 | 0.1996 |
| Loa Loa (eye worm) | hypothetical protein | 0.01 | 0.1137 | 0.3027 |
| Loa Loa (eye worm) | hypothetical protein | 0.0019 | 0.0126 | 0.0334 |
| Trichomonas vaginalis | aldo-keto reductase, putative | 0.0038 | 0.0368 | 0.4498 |
| Echinococcus granulosus | GPCR family 2 | 0.0032 | 0.0287 | 0.0287 |
| Trichomonas vaginalis | aldo-keto reductase, putative | 0.0038 | 0.0368 | 0.4498 |
| Onchocerca volvulus | 0.002 | 0.0138 | 0.0369 | |
| Brugia malayi | Nuclear hormone receptor family member nhr-19 | 0.004 | 0.0385 | 0.1025 |
| Toxoplasma gondii | zinc finger CDGSH-type domain-containing protein | 0.0035 | 0.0323 | 0.2422 |
| Onchocerca volvulus | 0.0071 | 0.0779 | 0.2586 | |
| Trichomonas vaginalis | multidrug resistance protein 1, 2, putative | 0.0025 | 0.0209 | 0.2381 |
| Echinococcus granulosus | carnitine O palmitoyltransferase 1 liver | 0.0107 | 0.1224 | 0.1224 |
| Trichomonas vaginalis | conserved hypothetical protein | 0.0013 | 0.0055 | 0.0315 |
| Loa Loa (eye worm) | oxidoreductase | 0.0038 | 0.0368 | 0.0979 |
| Entamoeba histolytica | aldose reductase, putative | 0.0038 | 0.0368 | 1 |
| Trichomonas vaginalis | dihydrodiol dehydrogenase, putative | 0.0038 | 0.0368 | 0.4498 |
| Mycobacterium tuberculosis | Probable aldehyde dehydrogenase | 0.0073 | 0.0802 | 0.0949 |
| Echinococcus granulosus | tyrosine protein kinase Src42A | 0.004 | 0.0386 | 0.0386 |
| Schistosoma mansoni | tyrosine kinase | 0.001 | 0.0021 | 0.0021 |
| Mycobacterium ulcerans | esterase/lipase LipP | 0.0071 | 0.0779 | 0.0856 |
| Schistosoma mansoni | potassium channel beta | 0.0011 | 0.0031 | 0.0031 |
| Giardia lamblia | Aldose reductase | 0.0038 | 0.0368 | 1 |
| Echinococcus multilocularis | tyrosine protein kinase Abl | 0.001 | 0.0021 | 0.0021 |
| Trypanosoma brucei | carnitine O-acetyltransferase, putative | 0.002 | 0.0138 | 0.0633 |
| Echinococcus granulosus | choline O acetyltransferase | 0.002 | 0.0138 | 0.0138 |
| Echinococcus multilocularis | ecdysone induced protein 78C | 0.004 | 0.0385 | 0.0385 |
| Echinococcus granulosus | multidrug resistance protein 1 | 0.0018 | 0.0114 | 0.0114 |
| Echinococcus multilocularis | choline O acetyltransferase | 0.002 | 0.0138 | 0.0138 |
| Brugia malayi | oxidoreductase, aldo/keto reductase family protein | 0.0038 | 0.0368 | 0.0979 |
| Brugia malayi | hypothetical protein | 0.0019 | 0.0126 | 0.0334 |
| Schistosoma mansoni | RAR-like nuclear receptor | 0.004 | 0.0385 | 0.0385 |
| Echinococcus granulosus | tyrosine protein kinase Fyn | 0.0045 | 0.0457 | 0.0457 |
| Trichomonas vaginalis | chromodomain helicase DNA binding protein, putative | 0.0013 | 0.0055 | 0.0315 |
| Loa Loa (eye worm) | hypothetical protein | 0.0032 | 0.0287 | 0.0764 |
| Schistosoma mansoni | multidrug resistance protein | 0.0025 | 0.0209 | 0.0209 |
| Trichomonas vaginalis | ABC transporter, putative | 0.0025 | 0.0209 | 0.2381 |
| Trypanosoma brucei | apurinic/apyrimidinic endonuclease, putative | 0.0023 | 0.0175 | 0.0854 |
| Echinococcus multilocularis | histone lysine N methyltransferase MLL3 | 0.0018 | 0.0113 | 0.0113 |
| Brugia malayi | RE40412p | 0.0035 | 0.0323 | 0.0861 |
| Brugia malayi | photoreceptor-specific nuclear receptor | 0.004 | 0.0385 | 0.1025 |
| Echinococcus granulosus | multidrug resistance protein 1 | 0.0018 | 0.0114 | 0.0114 |
| Trichomonas vaginalis | helicase, putative | 0.0013 | 0.0055 | 0.0315 |
| Echinococcus granulosus | aldehyde reductase | 0.0027 | 0.023 | 0.023 |
| Echinococcus multilocularis | nuclear receptor subfamily 4 group A | 0.0019 | 0.0126 | 0.0126 |
| Echinococcus granulosus | aldo keto reductase | 0.0038 | 0.0368 | 0.0368 |
| Brugia malayi | nuclear receptor RXR | 0.0021 | 0.0153 | 0.0408 |
| Schistosoma mansoni | thyroid hormone receptor | 0.004 | 0.0385 | 0.0385 |
| Schistosoma mansoni | hypothetical protein | 0.0053 | 0.0547 | 0.0547 |
| Brugia malayi | Choline/Carnitine o-acyltransferase family protein | 0.002 | 0.0138 | 0.0367 |
| Echinococcus multilocularis | growth factor receptor bound protein 2 | 0.0009 | 0.0005 | 0.0005 |
| Brugia malayi | nuclear receptor NHR-88 | 0.004 | 0.0385 | 0.1025 |
| Brugia malayi | Nuclear hormone receptor family member nhr-41 | 0.004 | 0.0385 | 0.1025 |
| Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0046 | 0.046 | 0.046 |
| Mycobacterium tuberculosis | Probable esterase LipL | 0.0071 | 0.0779 | 0.0921 |
| Echinococcus granulosus | Nuclear hormone receptor HR96 | 0.0019 | 0.0126 | 0.0126 |
| Schistosoma mansoni | nuclear hormone receptor | 0.0019 | 0.0126 | 0.0126 |
| Loa Loa (eye worm) | hypothetical protein | 0.0312 | 0.3755 | 1 |
| Loa Loa (eye worm) | hypothetical protein | 0.0025 | 0.0209 | 0.0557 |
| Echinococcus multilocularis | nuclear receptor subfamily 1 group D | 0.0021 | 0.0153 | 0.0153 |
| Echinococcus granulosus | aldo keto reductase family 1 member B4 | 0.0038 | 0.0368 | 0.0368 |
| Loa Loa (eye worm) | hypothetical protein | 0.0053 | 0.0547 | 0.1456 |
| Schistosoma mansoni | amine oxidase | 0.0051 | 0.0519 | 0.0519 |
| Leishmania major | aldehyde reductase, putative,oxidoreductase, putative | 0.0038 | 0.0368 | 0.1996 |
| Trypanosoma cruzi | hypothetical protein, conserved | 0.002 | 0.0138 | 0.0633 |
| Loa Loa (eye worm) | hypothetical protein | 0.0071 | 0.0779 | 0.2075 |
| Echinococcus multilocularis | aldo keto reductase family 1, member B4 | 0.0038 | 0.0368 | 0.0368 |
| Brugia malayi | F/Y-rich N-terminus family protein | 0.0018 | 0.0111 | 0.0294 |
| Brugia malayi | Sex muscle abnormal protein 5 | 0.0009 | 0.0005 | 0.0013 |
| Trichomonas vaginalis | ap endonuclease, putative | 0.0023 | 0.0175 | 0.1925 |
| Loa Loa (eye worm) | hypothetical protein | 0.004 | 0.0385 | 0.1025 |
| Loa Loa (eye worm) | choline O-acetyltransferase | 0.002 | 0.0138 | 0.0367 |
| Loa Loa (eye worm) | hypothetical protein | 0.0019 | 0.0126 | 0.0334 |
| Echinococcus granulosus | COUP TF:Svp nuclear hormone receptor | 0.004 | 0.0385 | 0.0385 |
| Trichomonas vaginalis | ATP-binding cassette transporter, putative | 0.0025 | 0.0209 | 0.2381 |
| Echinococcus multilocularis | tyrosine protein kinase Src42A | 0.004 | 0.0386 | 0.0386 |
| Leishmania major | carnitine/choline acetyltransferase, putative | 0.002 | 0.0138 | 0.0633 |
| Trichomonas vaginalis | chromodomain-helicase-DNA-binding protein, putative | 0.0013 | 0.0055 | 0.0315 |
| Onchocerca volvulus | 0.0038 | 0.0368 | 0.1163 | |
| Loa Loa (eye worm) | MH2 domain-containing protein | 0.0126 | 0.1452 | 0.3867 |
| Loa Loa (eye worm) | hypothetical protein | 0.0019 | 0.0126 | 0.0334 |
| Echinococcus granulosus | tyrosine protein kinase Lyn | 0.0045 | 0.0457 | 0.0457 |
| Trichomonas vaginalis | conserved hypothetical protein | 0.0013 | 0.0055 | 0.0315 |
| Schistosoma mansoni | cpg binding protein | 0.0057 | 0.0603 | 0.0603 |
| Onchocerca volvulus | Protein ultraspiracle homolog | 0.004 | 0.0385 | 0.1224 |
| Trichomonas vaginalis | ABC transporter, putative | 0.0025 | 0.0209 | 0.2381 |
| Schistosoma mansoni | ecdysone-induced protein 78c (dr-78) | 0.0021 | 0.0153 | 0.0153 |
| Trichomonas vaginalis | aldo-keto reductase, putative | 0.0038 | 0.0368 | 0.4498 |
| Schistosoma mansoni | hypothetical protein | 0.0035 | 0.0323 | 0.0323 |
| Echinococcus granulosus | baculoviral IAP repeat containing protein | 0.0053 | 0.0547 | 0.0547 |
| Brugia malayi | Nuclear hormone receptor family member nhr-25 | 0.004 | 0.0385 | 0.1025 |
| Trypanosoma cruzi | apurinic/apyrimidinic endonuclease, putative | 0.0023 | 0.0175 | 0.0854 |
| Loa Loa (eye worm) | nuclear hormone receptor family member nhr-31 | 0.004 | 0.0385 | 0.1025 |
| Echinococcus granulosus | ATP binding cassette subfamily B MDR:TAP | 0.0025 | 0.0209 | 0.0209 |
| Onchocerca volvulus | Nuclear receptor subfamily 6 group A member 1 homolog | 0.0019 | 0.0126 | 0.0327 |
| Loa Loa (eye worm) | hypothetical protein | 0.0051 | 0.0519 | 0.1383 |
| Schistosoma mansoni | Protoporphyrinogen oxidase chloroplast/mitochondrial precursor | 0.0051 | 0.0519 | 0.0519 |
| Brugia malayi | Nuclear hormone receptor-like 1 | 0.0021 | 0.0153 | 0.0408 |
| Trichomonas vaginalis | abcb9, putative | 0.0025 | 0.0209 | 0.2381 |
| Echinococcus granulosus | carbonic anhydrase | 0.0034 | 0.0309 | 0.0309 |
| Mycobacterium leprae | Conserved hypothetical protein | 0.0027 | 0.023 | 0.2664 |
| Leishmania major | aldo-keto reductase-like protein | 0.0038 | 0.0368 | 0.1996 |
| Loa Loa (eye worm) | hypothetical protein | 0.0021 | 0.0153 | 0.0408 |
| Loa Loa (eye worm) | hypothetical protein | 0.0053 | 0.0547 | 0.1456 |
| Brugia malayi | hypothetical protein | 0.0019 | 0.0126 | 0.0334 |
| Loa Loa (eye worm) | hypothetical protein | 0.0034 | 0.0309 | 0.0824 |
| Echinococcus granulosus | diuretic hormone 44 receptor GPRdih2 | 0.0032 | 0.0287 | 0.0287 |
| Echinococcus multilocularis | diuretic hormone 44 receptor GPRdih2 | 0.0032 | 0.0287 | 0.0287 |
| Trichomonas vaginalis | ATP-binding cassette transporter, putative | 0.0025 | 0.0209 | 0.2381 |
| Echinococcus granulosus | nuclear receptor subfamily 1 group D | 0.0021 | 0.0153 | 0.0153 |
| Loa Loa (eye worm) | glutamate-cysteine ligase modifier subunit | 0.0011 | 0.0031 | 0.0083 |
| Leishmania major | prostaglandin f synthase, putative | 0.0038 | 0.0368 | 0.1996 |
| Brugia malayi | Eukaryotic-type carbonic anhydrase family protein | 0.0034 | 0.0309 | 0.0824 |
| Schistosoma mansoni | Lysine-specific histone demethylase 1 | 0.0051 | 0.0519 | 0.0519 |
| Echinococcus granulosus | tyrosine protein kinase Fyn | 0.0045 | 0.0457 | 0.0457 |
| Brugia malayi | Eukaryotic-type carbonic anhydrase family protein | 0.0034 | 0.0309 | 0.0824 |
| Echinococcus multilocularis | COUP TF:Svp nuclear hormone receptor | 0.004 | 0.0385 | 0.0385 |
| Echinococcus granulosus | Nuclear hormone receptor family member nhr 41 | 0.004 | 0.0385 | 0.0385 |
| Brugia malayi | Hypothetical 52.5 kDa protein ZK945.1 in chromosome II, putative | 0.0071 | 0.0779 | 0.2075 |
| Mycobacterium tuberculosis | Probable transmembrane multidrug efflux pump | 0.0025 | 0.0209 | 0.0219 |
| Brugia malayi | Steroid receptor seven-up type 2 | 0.004 | 0.0385 | 0.1025 |
| Schistosoma mansoni | aldehyde dehydrogenase | 0.0073 | 0.0802 | 0.0802 |
| Toxoplasma gondii | histone lysine-specific demethylase | 0.0051 | 0.0519 | 0.4045 |
| Echinococcus multilocularis | retinoic acid receptor rxr beta a retinoic acid receptor rxr alpha a retinoic acid receptor rxr alpha | 0.0019 | 0.0126 | 0.0126 |
| Loa Loa (eye worm) | TK protein kinase | 0.0036 | 0.0346 | 0.0921 |
| Echinococcus multilocularis | aldo keto reductase family 1, member B4 | 0.0038 | 0.0368 | 0.0368 |
| Onchocerca volvulus | 0.0038 | 0.0368 | 0.1163 | |
| Echinococcus granulosus | tyrosine kinase | 0.0041 | 0.0402 | 0.0402 |
| Echinococcus granulosus | aldo keto reductase | 0.0038 | 0.0368 | 0.0368 |
| Loa Loa (eye worm) | hypothetical protein | 0.0019 | 0.0126 | 0.0334 |
| Schistosoma mansoni | nuclear hormone receptor | 0.004 | 0.0385 | 0.0385 |
| Toxoplasma gondii | PfMNL-2 CISD1 family iron-sulfur protein, putative | 0.0035 | 0.0323 | 0.2422 |
| Schistosoma mansoni | nck2/grb4 | 0.0009 | 0.0005 | 0.0005 |
| Trichomonas vaginalis | taga, putative | 0.0025 | 0.0209 | 0.2381 |
| Echinococcus multilocularis | proto oncogene tyrosine protein kinase LCK | 0.0045 | 0.0457 | 0.0457 |
| Loa Loa (eye worm) | hypothetical protein | 0.0071 | 0.0779 | 0.2075 |
| Toxoplasma gondii | ABC1 family protein | 0.0071 | 0.0779 | 0.6197 |
| Loa Loa (eye worm) | hypothetical protein | 0.0051 | 0.0519 | 0.1383 |
| Schistosoma mansoni | choline o-acyltransferase | 0.002 | 0.0138 | 0.0138 |
| Plasmodium falciparum | protoporphyrinogen oxidase | 0.0051 | 0.0519 | 1 |
| Brugia malayi | NADH-dependent xylose reductase | 0.0011 | 0.0031 | 0.0083 |
| Trichomonas vaginalis | chromodomain helicase DNA binding protein, putative | 0.0013 | 0.0055 | 0.0315 |
| Echinococcus granulosus | FTZ F1 alpha | 0.004 | 0.0385 | 0.0385 |
| Schistosoma mansoni | nuclear hormone receptor superfamily protein-related | 0.0435 | 0.5286 | 0.5286 |
| Schistosoma mansoni | hypothetical protein | 0.0069 | 0.0743 | 0.0743 |
| Echinococcus multilocularis | aldo keto reductase | 0.0038 | 0.0368 | 0.0368 |
| Brugia malayi | Inhibitor of Apoptosis domain containing protein | 0.0053 | 0.0547 | 0.1456 |
| Toxoplasma gondii | zinc finger cdgsh type protein | 0.0035 | 0.0323 | 0.2422 |
| Brugia malayi | conserved hypotetical protein | 0.0019 | 0.0126 | 0.0334 |
| Entamoeba histolytica | protein kinase, putative | 0.0036 | 0.0346 | 0.935 |
| Trypanosoma cruzi | hypothetical protein, conserved | 0.002 | 0.0138 | 0.0633 |
| Mycobacterium ulcerans | exodeoxyribonuclease III protein XthA | 0.0023 | 0.0175 | 0.0165 |
| Trypanosoma brucei | carnitine O-palmitoyltransferase II, putative | 0.002 | 0.0138 | 0.0633 |
| Trichomonas vaginalis | lipid A export ATP-binding/permease protein msba, putative | 0.0025 | 0.0209 | 0.2381 |
| Toxoplasma gondii | ABC transporter transmembrane region domain-containing protein | 0.0025 | 0.0209 | 0.1476 |
| Echinococcus granulosus | lysine specific histone demethylase 1A | 0.0051 | 0.0519 | 0.0519 |
| Onchocerca volvulus | 0.0071 | 0.0779 | 0.2586 | |
| Leishmania major | carbonic anhydrase-like protein | 0.0147 | 0.1717 | 1 |
| Loa Loa (eye worm) | hypothetical protein | 0.0021 | 0.0153 | 0.0408 |
| Schistosoma mansoni | family S12 unassigned peptidase (S12 family) | 0.0071 | 0.0779 | 0.0779 |
| Trichomonas vaginalis | multidrug resistance protein 1, 2, putative | 0.0025 | 0.0209 | 0.2381 |
| Mycobacterium ulcerans | aldehyde dehydrogenase | 0.0073 | 0.0802 | 0.0882 |
| Onchocerca volvulus | 0.004 | 0.0385 | 0.1224 | |
| Giardia lamblia | Aldose reductase | 0.0038 | 0.0368 | 1 |
| Trichomonas vaginalis | chromodomain-helicase-DNA-binding protein, putative | 0.0013 | 0.0055 | 0.0315 |
| Echinococcus multilocularis | mixed lineage leukemia protein mll | 0.0014 | 0.007 | 0.007 |
| Schistosoma mansoni | hypothetical protein | 0.0032 | 0.0287 | 0.0287 |
| Schistosoma mansoni | nuclear receptor 2DBD-gamma | 0.004 | 0.0385 | 0.0385 |
| Brugia malayi | nuclear hormone receptor family member odr-7 | 0.0019 | 0.0126 | 0.0334 |
| Schistosoma mansoni | hypothetical protein | 0.0816 | 1 | 1 |
| Leishmania major | ATP-binding cassette protein subfamily B, member 2, putative | 0.0025 | 0.0209 | 0.1057 |
| Mycobacterium tuberculosis | Conserved protein | 0.0071 | 0.0779 | 0.0921 |
| Entamoeba histolytica | aldose reductase, putative | 0.0038 | 0.0368 | 1 |
| Echinococcus granulosus | growth factor receptor bound protein 2 | 0.0009 | 0.0005 | 0.0005 |
| Toxoplasma gondii | exonuclease III APE | 0.0023 | 0.0175 | 0.1193 |
| Brugia malayi | Calcitonin receptor-like protein seb-1 | 0.01 | 0.1137 | 0.3027 |
| Brugia malayi | Nuclear hormone receptor family member nhr-14 | 0.004 | 0.0385 | 0.1025 |
| Schistosoma mansoni | multidrug resistance protein | 0.0025 | 0.0209 | 0.0209 |
| Brugia malayi | Choline O-acetyltransferase | 0.002 | 0.0138 | 0.0367 |
| Schistosoma mansoni | steroid hormone receptor ad4bp | 0.004 | 0.0385 | 0.0385 |
| Onchocerca volvulus | 0.0019 | 0.0126 | 0.0327 | |
| Loa Loa (eye worm) | nuclear hormone receptor-like 1 | 0.0021 | 0.0153 | 0.0408 |
| Brugia malayi | Inhibitor of Apoptosis domain containing protein | 0.0053 | 0.0547 | 0.1456 |
| Plasmodium falciparum | CDGSH iron-sulfur domain-containing protein, putative | 0.0035 | 0.0323 | 0.5988 |
| Loa Loa (eye worm) | latrophilin receptor protein 2 | 0.0032 | 0.0287 | 0.0764 |
| Loa Loa (eye worm) | hypothetical protein | 0.0034 | 0.0309 | 0.0824 |
| Schistosoma mansoni | tyrosine kinase | 0.0045 | 0.0457 | 0.0457 |
| Loa Loa (eye worm) | nuclear hormone receptor family member nhr-1 | 0.004 | 0.0385 | 0.1025 |
| Trichomonas vaginalis | aldo/keto reductase, putative | 0.0038 | 0.0368 | 0.4498 |
| Echinococcus granulosus | nuclear receptor subfamily 4 group A | 0.0019 | 0.0126 | 0.0126 |
| Trypanosoma cruzi | choline/carnitine O-acyltransferase, putative | 0.0107 | 0.1224 | 0.7078 |
| Echinococcus granulosus | carbonic anhydrase | 0.0034 | 0.0309 | 0.0309 |
| Mycobacterium ulcerans | dehydrogenase | 0.0051 | 0.0519 | 0.0558 |
| Leishmania major | choline/Carnitine o-acyltransferase-like protein | 0.0107 | 0.1224 | 0.7078 |
| Trypanosoma cruzi | carnitine O-acetyltransferase, putative | 0.002 | 0.0138 | 0.0633 |
| Echinococcus granulosus | 5'partial|ATP binding cassette sub family B | 0.0025 | 0.0206 | 0.0206 |
| Mycobacterium ulcerans | monoamine oxidase | 0.0051 | 0.0519 | 0.0558 |
| Echinococcus granulosus | cadherin EGF LAG seven pass G type receptor | 0.0032 | 0.0287 | 0.0287 |
| Leishmania major | UDP-galactopyranose mutase | 0.0051 | 0.0519 | 0.2896 |
| Brugia malayi | Carbonic anhydrase like protein 2 precursor | 0.0034 | 0.0309 | 0.0824 |
| Plasmodium vivax | protoporphyrinogen oxidase, putative | 0.0051 | 0.0519 | 0.6526 |
| Trichomonas vaginalis | ATP-binding cassette transporter, putative | 0.0025 | 0.0209 | 0.2381 |
| Trypanosoma brucei | carnitine O-palmitoyltransferase, putative | 0.002 | 0.0138 | 0.0633 |
| Echinococcus multilocularis | tyrosine protein kinase Fyn | 0.0045 | 0.0457 | 0.0457 |
| Trypanosoma cruzi | UDP-galactopyranose mutase | 0.0051 | 0.0519 | 0.2896 |
| Brugia malayi | oxidoreductase, aldo/keto reductase family protein | 0.0038 | 0.0368 | 0.0979 |
| Onchocerca volvulus | 0.0053 | 0.0547 | 0.1782 | |
| Toxoplasma gondii | aldehyde dehydrogenase | 0.0073 | 0.0802 | 0.6386 |
| Loa Loa (eye worm) | nuclear hormone receptor family member nhr-40 | 0.004 | 0.0385 | 0.1025 |
| Loa Loa (eye worm) | histone methyltransferase | 0.0018 | 0.0113 | 0.0302 |
| Trypanosoma cruzi | carnitine O-palmitoyltransferase II, putative | 0.002 | 0.0138 | 0.0633 |
| Echinococcus multilocularis | aldo keto reductase family 1, member B4 | 0.0038 | 0.0368 | 0.0368 |
| Toxoplasma gondii | ATP-binding cassette transporter ABC.B1 | 0.0025 | 0.0209 | 0.1476 |
| Echinococcus multilocularis | ATP binding cassette subfamily B (MDR:TAP) | 0.0025 | 0.0209 | 0.0209 |
| Brugia malayi | ABC transporter family protein | 0.0025 | 0.0209 | 0.0557 |
| Mycobacterium tuberculosis | Probable oxidoreductase | 0.0038 | 0.0368 | 0.0414 |
| Echinococcus multilocularis | protoporphyrinogen oxidase | 0.0051 | 0.0519 | 0.0519 |
| Trichomonas vaginalis | aldo-keto reductase, putative | 0.0038 | 0.0368 | 0.4498 |
| Trypanosoma cruzi | carnitine/choline acetyltransferase, putative | 0.002 | 0.0138 | 0.0633 |
| Mycobacterium leprae | Probable lipase LipE | 0.0071 | 0.0779 | 1 |
| Schistosoma mansoni | choline o-acyltransferase | 0.002 | 0.0138 | 0.0138 |
| Leishmania major | carnitine palmitoyltransferase-like protein | 0.002 | 0.0138 | 0.0633 |
| Echinococcus multilocularis | carnitine O palmitoyltransferase 1, liver | 0.0107 | 0.1224 | 0.1224 |
| Mycobacterium ulcerans | hypothetical protein | 0.0071 | 0.0779 | 0.0856 |
| Trichomonas vaginalis | abcb9, putative | 0.0025 | 0.0209 | 0.2381 |
| Mycobacterium ulcerans | oxidoreductase | 0.0038 | 0.0368 | 0.0385 |
| Echinococcus multilocularis | aldo keto reductase family 1, member B4 | 0.0038 | 0.0368 | 0.0368 |
| Toxoplasma gondii | histone lysine-specific demethylase LSD1/BHC110/KDMA1A | 0.0054 | 0.0563 | 0.4403 |
| Loa Loa (eye worm) | hypothetical protein | 0.0035 | 0.0323 | 0.0861 |
| Loa Loa (eye worm) | hypothetical protein | 0.0034 | 0.0309 | 0.0824 |
| Schistosoma mansoni | hypothetical protein | 0.0032 | 0.0287 | 0.0287 |
| Echinococcus multilocularis | aldo keto reductase family 1, member B4 | 0.0038 | 0.0368 | 0.0368 |
| Echinococcus granulosus | NCK adaptor protein | 0.0009 | 0.0005 | 0.0005 |
| Brugia malayi | Nuclear hormone receptor E75 | 0.0019 | 0.0126 | 0.0334 |
| Mycobacterium tuberculosis | Probable hydrolase | 0.0071 | 0.0779 | 0.0921 |
| Echinococcus multilocularis | carbonic anhydrase | 0.0034 | 0.0309 | 0.0309 |
| Loa Loa (eye worm) | exodeoxyribonuclease III family protein | 0.0023 | 0.0175 | 0.0466 |
| Trichomonas vaginalis | conserved hypothetical protein | 0.0013 | 0.0055 | 0.0315 |
| Echinococcus granulosus | retinoic acid receptor rxr beta a | 0.004 | 0.0385 | 0.0385 |
| Echinococcus multilocularis | tyrosine protein kinase Fyn | 0.0045 | 0.0457 | 0.0457 |
| Schistosoma mansoni | ap endonuclease | 0.0023 | 0.0175 | 0.0175 |
| Echinococcus granulosus | multidrug resistance protein 1 | 0.0025 | 0.0209 | 0.0209 |
| Loa Loa (eye worm) | hypothetical protein | 0.0051 | 0.0519 | 0.1383 |
| Echinococcus multilocularis | aldo keto reductase | 0.0038 | 0.0368 | 0.0368 |
| Echinococcus multilocularis | tyrosine protein kinase HCK | 0.0036 | 0.0346 | 0.0346 |
| Schistosoma mansoni | nuclear receptor | 0.0019 | 0.0126 | 0.0126 |
| Schistosoma mansoni | microtubule-associated protein tau | 0.0697 | 0.8525 | 0.8525 |
| Trichomonas vaginalis | ATP-binding cassette transporter, putative | 0.0018 | 0.0114 | 0.1108 |
| Trypanosoma cruzi | hypothetical protein, conserved | 0.0071 | 0.0779 | 0.4438 |
| Echinococcus granulosus | tyrosine protein kinase Blk | 0.0041 | 0.0402 | 0.0402 |
| Onchocerca volvulus | 0.0035 | 0.0323 | 0.1011 | |
| Echinococcus multilocularis | aldo keto reductase family 1, member B4 | 0.0038 | 0.0368 | 0.0368 |
| Schistosoma mansoni | carbonic anhydrase II (carbonate dehydratase II) | 0.0147 | 0.1717 | 0.1717 |
| Loa Loa (eye worm) | nuclear receptor nhr-7B | 0.0019 | 0.0126 | 0.0334 |
| Loa Loa (eye worm) | hypothetical protein | 0.0009 | 0.0005 | 0.0013 |
| Echinococcus granulosus | tyrosine kinase|tyrosine protein kinase Fyn | 0.0041 | 0.0402 | 0.0402 |
| Schistosoma mansoni | adapter molecule crk | 0.0009 | 0.0005 | 0.0005 |
| Brugia malayi | beta-lactamase family protein | 0.0071 | 0.0779 | 0.2075 |
| Echinococcus multilocularis | aldo keto reductase family 1, member B4 | 0.0038 | 0.0368 | 0.0368 |
| Echinococcus multilocularis | tyrosine protein kinase Btk29A | 0.001 | 0.0021 | 0.0021 |
| Onchocerca volvulus | 0.0038 | 0.0368 | 0.1163 | |
| Trichomonas vaginalis | conserved hypothetical protein | 0.0013 | 0.0055 | 0.0315 |
| Echinococcus multilocularis | nuclear receptor 2DBD gamma | 0.004 | 0.0385 | 0.0385 |
| Brugia malayi | amine oxidase, flavin-containing family protein | 0.0051 | 0.0519 | 0.1383 |
| Brugia malayi | Choline/Carnitine o-acyltransferase family protein | 0.0312 | 0.3755 | 1 |
| Brugia malayi | protein-tyrosine kinase | 0.0041 | 0.0402 | 0.1071 |
| Leishmania major | apurinic/apyrimidinic endonuclease-redox protein | 0.0023 | 0.0175 | 0.0854 |
| Echinococcus multilocularis | tyrosine protein kinase Src64B | 0.0045 | 0.0457 | 0.0457 |
| Echinococcus multilocularis | aldehyde dehydrogenase, mitochondrial | 0.0073 | 0.0802 | 0.0802 |
| Loa Loa (eye worm) | hypothetical protein | 0.0021 | 0.0153 | 0.0408 |
| Brugia malayi | ecdysteroid receptor | 0.004 | 0.0385 | 0.1025 |
| Loa Loa (eye worm) | hypothetical protein | 0.0019 | 0.0126 | 0.0334 |
| Echinococcus granulosus | histone lysine N methyltransferase MLL3 | 0.0014 | 0.007 | 0.007 |
| Loa Loa (eye worm) | hypothetical protein | 0.0021 | 0.0153 | 0.0408 |
| Echinococcus granulosus | nuclear receptor nhr 48 | 0.0019 | 0.0126 | 0.0126 |
| Echinococcus multilocularis | aldo keto reductase family 1, member B4 | 0.0038 | 0.0368 | 0.0368 |
| Echinococcus granulosus | ATP binding cassette subfamily B MDR:TAP | 0.0025 | 0.0209 | 0.0209 |
| Echinococcus multilocularis | nuclear receptor 2DBD gamma | 0.004 | 0.0385 | 0.0385 |
| Loa Loa (eye worm) | hypothetical protein | 0.0051 | 0.0519 | 0.1383 |
| Loa Loa (eye worm) | beta-lactamase | 0.0071 | 0.0779 | 0.2075 |
| Echinococcus granulosus | multidrug resistance protein 1 | 0.0025 | 0.0209 | 0.0209 |
| Mycobacterium tuberculosis | Possible oxidoreductase | 0.0051 | 0.0519 | 0.0601 |
| Echinococcus multilocularis | tyrosine protein kinase Src42A | 0.0045 | 0.0457 | 0.0457 |
| Onchocerca volvulus | 0.0245 | 0.2924 | 1 | |
| Plasmodium falciparum | conserved Plasmodium protein, unknown function | 0.0051 | 0.0519 | 1 |
| Brugia malayi | nuclear receptor NHR-88 | 0.0019 | 0.0126 | 0.0334 |
| Toxoplasma gondii | aldose reductase, putative | 0.0038 | 0.0368 | 0.2788 |
| Loa Loa (eye worm) | ATP-binding cassette sub-family B member 2 | 0.0025 | 0.0209 | 0.0557 |
| Echinococcus multilocularis | multidrug resistance protein 1 | 0.0025 | 0.0209 | 0.0209 |
| Mycobacterium tuberculosis | Possible conserved lipoprotein LpqK | 0.0071 | 0.0779 | 0.0921 |
| Trichomonas vaginalis | D-aminoacylase, putative | 0.0071 | 0.0779 | 1 |
| Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0046 | 0.046 | 0.046 |
| Schistosoma mansoni | cpg binding protein | 0.0061 | 0.0644 | 0.0644 |
| Plasmodium falciparum | lysine-specific histone demethylase 1, putative | 0.0051 | 0.0519 | 1 |
| Loa Loa (eye worm) | hypothetical protein | 0.0019 | 0.0126 | 0.0334 |
| Echinococcus granulosus | Nuclear hormone receptor HR96 | 0.0019 | 0.0126 | 0.0126 |
| Plasmodium vivax | hypothetical protein, conserved | 0.0035 | 0.0323 | 0.3908 |
| Echinococcus multilocularis | conserved hypothetical protein | 0.0035 | 0.0323 | 0.0323 |
| Echinococcus granulosus | ecdysone induced protein 78C | 0.004 | 0.0385 | 0.0385 |
| Plasmodium vivax | multidrug resistance protein 1, putative | 0.0025 | 0.0209 | 0.2381 |
| Brugia malayi | oxidoreductase, aldo/keto reductase family protein | 0.0038 | 0.0368 | 0.0979 |
| Trichomonas vaginalis | aldo-keto reductase, putative | 0.0038 | 0.0368 | 0.4498 |
| Trichomonas vaginalis | aldo-keto reductase, putative | 0.0038 | 0.0368 | 0.4498 |
| Loa Loa (eye worm) | steroid hormone receptor | 0.004 | 0.0385 | 0.1025 |
| Schistosoma mansoni | hypothetical protein | 0.0032 | 0.0287 | 0.0287 |
| Loa Loa (eye worm) | hypothetical protein | 0.002 | 0.0138 | 0.0367 |
| Loa Loa (eye worm) | beta-LACTamase domain containing family member | 0.0071 | 0.0779 | 0.2075 |
| Schistosoma mansoni | retinoid-x-receptor (RXR) | 0.004 | 0.0385 | 0.0385 |
| Loa Loa (eye worm) | oxidoreductase | 0.0038 | 0.0368 | 0.0979 |
| Trichomonas vaginalis | aldo-keto reductase, putative | 0.0038 | 0.0368 | 0.4498 |
| Loa Loa (eye worm) | nuclear Hormone Receptor family member | 0.004 | 0.0385 | 0.1025 |
| Trichomonas vaginalis | penicillin-binding protein, putative | 0.0071 | 0.0779 | 1 |
| Brugia malayi | glutamate-cysteine ligase modifier subunit | 0.0011 | 0.0031 | 0.0083 |
| Plasmodium vivax | AP endonuclease (DNA-[apurinic or apyrimidinic site] lyase), putative | 0.0023 | 0.0175 | 0.1925 |
| Echinococcus granulosus | aldo keto reductase | 0.0038 | 0.0368 | 0.0368 |
| Echinococcus granulosus | aldo keto reductase family 1 member B4 | 0.0038 | 0.0368 | 0.0368 |
| Echinococcus multilocularis | lysine specific histone demethylase 1A | 0.0051 | 0.0519 | 0.0519 |
| Echinococcus granulosus | mixed lineage leukemia protein mll | 0.0014 | 0.007 | 0.007 |
| Brugia malayi | Corticotropin releasing factor receptor 2 precursor, putative | 0.01 | 0.1137 | 0.3027 |
| Trypanosoma cruzi | carbonic anhydrase-like protein, putative | 0.0147 | 0.1717 | 1 |
| Brugia malayi | oxidoreductase, aldo/keto reductase family protein | 0.0038 | 0.0368 | 0.0979 |
| Schistosoma mansoni | nuclear hormone receptor | 0.0019 | 0.0126 | 0.0126 |
| Echinococcus granulosus | 3'partial|tyrosine protein kinase Fgr | 0.0045 | 0.0457 | 0.0457 |
| Echinococcus multilocularis | ATP binding cassette sub family B | 0.0025 | 0.0206 | 0.0206 |
| Trypanosoma cruzi | carbonic anhydrase-like protein, putative | 0.0147 | 0.1717 | 1 |
| Loa Loa (eye worm) | hypothetical protein | 0.0019 | 0.0126 | 0.0334 |
| Schistosoma mansoni | mixed-lineage leukemia protein mll | 0.0014 | 0.007 | 0.007 |
| Loa Loa (eye worm) | hypothetical protein | 0.004 | 0.0385 | 0.1025 |
| Echinococcus granulosus | tyrosine protein kinase Btk29A | 0.001 | 0.0021 | 0.0021 |
| Brugia malayi | Latrophilin receptor protein 2 | 0.0032 | 0.0287 | 0.0764 |
| Mycobacterium ulcerans | flavin-containing monoamine oxidase AofH | 0.0717 | 0.8775 | 1 |
| Brugia malayi | Nuclear hormone receptor family member nhr-31 | 0.004 | 0.0385 | 0.1025 |
| Brugia malayi | Ligand-binding domain of nuclear hormone receptor family protein | 0.004 | 0.0385 | 0.1025 |
| Trichomonas vaginalis | D-aminoacylase, putative | 0.0071 | 0.0779 | 1 |
| Mycobacterium ulcerans | aldehyde dehydrogenase | 0.0073 | 0.0802 | 0.0882 |
| Echinococcus multilocularis | Nuclear hormone receptor family member nhr 41 | 0.004 | 0.0385 | 0.0385 |
| Trypanosoma cruzi | aldo-keto reductase | 0.0038 | 0.0368 | 0.1996 |
| Onchocerca volvulus | 0.0071 | 0.0779 | 0.2586 | |
| Trichomonas vaginalis | ATP-binding cassette transporter, putative | 0.0025 | 0.0209 | 0.2381 |
| Echinococcus multilocularis | Nuclear hormone receptor HR96 | 0.0019 | 0.0126 | 0.0126 |
| Echinococcus multilocularis | ATP binding cassette subfamily B (MDR:TAP) | 0.0025 | 0.0209 | 0.0209 |
| Brugia malayi | Putative carbonic anhydrase 5 precursor | 0.0147 | 0.1717 | 0.4572 |
| Echinococcus granulosus | thyroid hormone receptor alpha | 0.0019 | 0.0126 | 0.0126 |
| Plasmodium vivax | hypothetical protein, conserved | 0.0035 | 0.0323 | 0.3908 |
| Schistosoma mansoni | smdr2 | 0.0025 | 0.0209 | 0.0209 |
| Loa Loa (eye worm) | hypothetical protein | 0.004 | 0.0385 | 0.1025 |
| Brugia malayi | Carbonic anhydrase like protein 2 precursor | 0.0034 | 0.0309 | 0.0824 |
| Echinococcus multilocularis | carbonic anhydrase | 0.0034 | 0.0309 | 0.0309 |
| Brugia malayi | Nuclear hormone receptor family member nhr-25 | 0.004 | 0.0385 | 0.1025 |
| Mycobacterium tuberculosis | Probable exodeoxyribonuclease III protein XthA (exonuclease III) (EXO III) (AP endonuclease VI) | 0.0023 | 0.0175 | 0.0177 |
| Trypanosoma cruzi | UDP-galactopyranose mutase | 0.0051 | 0.0519 | 0.2896 |
| Treponema pallidum | exodeoxyribonuclease (exoA) | 0.0023 | 0.0175 | 0.5 |
| Echinococcus multilocularis | cdgsh iron sulfur domain containing protein | 0.0575 | 0.702 | 0.702 |
| Onchocerca volvulus | 0.0038 | 0.0368 | 0.1163 | |
| Leishmania major | aldehyde dehydrogenase, mitochondrial precursor | 0.0073 | 0.0802 | 0.4573 |
| Trypanosoma brucei | hypothetical protein, conserved | 0.002 | 0.0138 | 0.0633 |
| Toxoplasma gondii | histone lysine methyltransferase SET1 | 0.0109 | 0.1238 | 1 |
| Echinococcus multilocularis | aldo keto reductase | 0.0038 | 0.0368 | 0.0368 |
| Trichomonas vaginalis | ABC transporter, half transporter, putative | 0.0025 | 0.0209 | 0.2381 |
| Echinococcus granulosus | carnitine O palmitoyltransferase 2 | 0.002 | 0.0138 | 0.0138 |
| Schistosoma mansoni | Tr4/Tr2 (homologue) | 0.004 | 0.0385 | 0.0385 |
| Loa Loa (eye worm) | SRC-1 | 0.0045 | 0.0457 | 0.1217 |
| Schistosoma mansoni | pol-related | 0.0038 | 0.0368 | 0.0368 |
| Brugia malayi | exodeoxyribonuclease III family protein | 0.0023 | 0.0175 | 0.0466 |
| Echinococcus granulosus | microtubule associated protein 2 | 0.0697 | 0.8525 | 0.8525 |
| Schistosoma mansoni | CDGSH-type Zn finger-containing protein-like protein | 0.061 | 0.745 | 0.745 |
| Schistosoma mansoni | carbonic anhydrase-related | 0.0034 | 0.0309 | 0.0309 |
| Loa Loa (eye worm) | hypothetical protein | 0.004 | 0.0385 | 0.1025 |
| Entamoeba histolytica | P-glycoprotein-5 | 0.0025 | 0.0209 | 0.5293 |
| Brugia malayi | nuclear hormone receptor | 0.004 | 0.0385 | 0.1025 |
| Echinococcus granulosus | aldo keto reductase family 1 member B4 | 0.0038 | 0.0368 | 0.0368 |
| Brugia malayi | Eukaryotic-type carbonic anhydrase family protein | 0.0147 | 0.1717 | 0.4572 |
| Echinococcus multilocularis | aldo keto reductase family 1, member B4 | 0.0038 | 0.0368 | 0.0368 |
| Schistosoma mansoni | coup transcription factor | 0.004 | 0.0385 | 0.0385 |
| Brugia malayi | nuclear hormone receptor | 0.0019 | 0.0126 | 0.0334 |
| Loa Loa (eye worm) | choline/Carnitine O-acyltransferase | 0.002 | 0.0138 | 0.0367 |
| Brugia malayi | Nuclear hormone receptor family member nhr-49 | 0.004 | 0.0385 | 0.1025 |
| Plasmodium falciparum | CDGSH iron-sulfur domain-containing protein, putative | 0.0035 | 0.0323 | 0.5988 |
| Brugia malayi | Ligand-binding domain of nuclear hormone receptor family protein | 0.004 | 0.0385 | 0.1025 |
| Echinococcus granulosus | FTZ F1 nuclear receptor protein | 0.004 | 0.0385 | 0.0385 |
| Echinococcus multilocularis | inhibitor of apoptosis protein | 0.0053 | 0.0547 | 0.0547 |
| Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0046 | 0.046 | 0.046 |
| Brugia malayi | Tyrosine-protein kinase abl-1 | 0.001 | 0.0021 | 0.0055 |
| Echinococcus granulosus | histone lysine N methyltransferase MLL3 | 0.0018 | 0.0113 | 0.0113 |
| Entamoeba histolytica | P-glycoprotein-2 | 0.0025 | 0.0209 | 0.5293 |
| Trypanosoma cruzi | carnitine/choline acetyltransferase, putative | 0.002 | 0.0138 | 0.0633 |
| Trichomonas vaginalis | chromodomain helicase DNA binding protein, putative | 0.0013 | 0.0055 | 0.0315 |
| Echinococcus multilocularis | aldo keto reductase | 0.0038 | 0.0368 | 0.0368 |
| Loa Loa (eye worm) | oxidoreductase | 0.0038 | 0.0368 | 0.0979 |
| Schistosoma mansoni | proto-oncogene tyrosine-protein kinase abl1 | 0.0009 | 0.0005 | 0.0005 |
| Toxoplasma gondii | hypothetical protein | 0.0034 | 0.0309 | 0.2306 |
| Echinococcus multilocularis | nuclear receptor nhr 48 | 0.0019 | 0.0126 | 0.0126 |
| Echinococcus multilocularis | dnaJ subfamily B | 0.0816 | 1 | 1 |
| Brugia malayi | Nuclear hormone receptor-like 1 | 0.0021 | 0.0153 | 0.0408 |
| Brugia malayi | beta-lactamase family protein | 0.0071 | 0.0779 | 0.2075 |
| Echinococcus granulosus | aldo keto reductase family 1, member B4 | 0.0011 | 0.0031 | 0.0031 |
| Loa Loa (eye worm) | hypothetical protein | 0.004 | 0.0385 | 0.1025 |
| Brugia malayi | Nuclear hormone receptor-like 1 | 0.004 | 0.0385 | 0.1025 |
| Trichomonas vaginalis | multidrug resistance protein 1, 2, putative | 0.0025 | 0.0209 | 0.2381 |
| Brugia malayi | Variant SH3 domain containing protein | 0.0009 | 0.0005 | 0.0013 |
| Schistosoma mansoni | tyrosine kinase | 0.0045 | 0.0457 | 0.0457 |
| Mycobacterium tuberculosis | Conserved hypothetical protein | 0.0051 | 0.0519 | 0.0601 |
| Trichomonas vaginalis | aldo-keto reductase, putative | 0.0038 | 0.0368 | 0.4498 |
| Loa Loa (eye worm) | hypothetical protein | 0.0071 | 0.0779 | 0.2075 |
| Trypanosoma cruzi | hypothetical protein, conserved | 0.002 | 0.0138 | 0.0633 |
| Echinococcus multilocularis | tyrosine protein kinase Fgr | 0.0045 | 0.0457 | 0.0457 |
| Onchocerca volvulus | 0.002 | 0.0138 | 0.0369 | |
| Onchocerca volvulus | Bile acid receptor homolog | 0.004 | 0.0385 | 0.1224 |
| Echinococcus granulosus | tyrosine protein kinase Src64B | 0.0045 | 0.0457 | 0.0457 |
| Brugia malayi | Nuclear hormone receptor family member nhr-1 | 0.004 | 0.0385 | 0.1025 |
| Brugia malayi | nuclear hormone receptor family member nhr-6 | 0.0019 | 0.0126 | 0.0334 |
| Loa Loa (eye worm) | hypothetical protein | 0.0019 | 0.0126 | 0.0334 |
| Echinococcus granulosus | tyrosine protein kinase HCK | 0.0036 | 0.0346 | 0.0346 |
| Plasmodium vivax | hypothetical protein, conserved | 0.0035 | 0.0323 | 0.3908 |
| Echinococcus granulosus | aldo keto reductase family 1 member B4 | 0.0038 | 0.0368 | 0.0368 |
| Echinococcus multilocularis | tyrosine protein kinase Blk | 0.0041 | 0.0402 | 0.0402 |
| Echinococcus multilocularis | ATP binding cassette subfamily B (MDR:TAP) | 0.0025 | 0.0209 | 0.0209 |
| Loa Loa (eye worm) | nuclear hormone receptor family member nhr-49 | 0.004 | 0.0385 | 0.1025 |
| Onchocerca volvulus | Nuclear receptor subfamily 6 group A member 1 homolog | 0.0019 | 0.0126 | 0.0327 |
| Echinococcus granulosus | tyrosine protein kinase Fyn | 0.0045 | 0.0457 | 0.0457 |
| Onchocerca volvulus | 0.0051 | 0.0519 | 0.1688 | |
| Mycobacterium tuberculosis | Probable esterase/lipase LipP | 0.0071 | 0.0779 | 0.0921 |
| Schistosoma mansoni | growth factor receptor-bound protein | 0.0009 | 0.0005 | 0.0005 |
| Loa Loa (eye worm) | multidrug resistance protein 3 | 0.0025 | 0.0209 | 0.0557 |
| Onchocerca volvulus | 0.0035 | 0.0323 | 0.1011 | |
| Brugia malayi | calcium-independent alpha-latrotoxin receptor 2, putative | 0.0032 | 0.0287 | 0.0764 |
| Loa Loa (eye worm) | hypothetical protein | 0.0019 | 0.0126 | 0.0334 |
| Leishmania major | prostaglandin f2-alpha synthase/D-arabinose dehydrogenase | 0.0038 | 0.0368 | 0.1996 |
| Loa Loa (eye worm) | sex muscle abnormal protein 5 | 0.0009 | 0.0005 | 0.0013 |
| Brugia malayi | Choline O-acetyltransferase | 0.002 | 0.0138 | 0.0367 |
| Echinococcus multilocularis | cpg binding protein | 0.0061 | 0.0644 | 0.0644 |
| Trichomonas vaginalis | aldo-keto reductase, putative | 0.0038 | 0.0368 | 0.4498 |
| Mycobacterium tuberculosis | Conserved protein | 0.0071 | 0.0779 | 0.0921 |
| Trichomonas vaginalis | lipid A export ATP-binding/permease protein msba, putative | 0.0025 | 0.0209 | 0.2381 |
| Trichomonas vaginalis | aldo-keto reductase, putative | 0.0038 | 0.0368 | 0.4498 |
| Echinococcus multilocularis | baculoviral IAP repeat containing protein | 0.0053 | 0.0547 | 0.0547 |
| Echinococcus granulosus | ATP binding cassette subfamily B MDR:TAP | 0.0025 | 0.0209 | 0.0209 |
| Brugia malayi | Nuclear hormone receptor family member nhr-19 | 0.004 | 0.0385 | 0.1025 |
| Brugia malayi | Variant SH3 domain containing protein | 0.0009 | 0.0005 | 0.0013 |
| Brugia malayi | Eukaryotic-type carbonic anhydrase family protein | 0.0034 | 0.0309 | 0.0824 |
| Schistosoma mansoni | mixed-lineage leukemia protein mll | 0.0122 | 0.1399 | 0.1399 |
| Schistosoma mansoni | aldo-keto reductase | 0.0038 | 0.0368 | 0.0368 |
| Echinococcus multilocularis | ATP binding cassette subfamily B (MDR:TAP) | 0.0025 | 0.0209 | 0.0209 |
| Entamoeba histolytica | P-glycoprotein-1 | 0.0025 | 0.0209 | 0.5293 |
| Brugia malayi | beta-lactamase | 0.0071 | 0.0779 | 0.2075 |
| Echinococcus multilocularis | cadherin EGF LAG seven pass G type receptor | 0.0032 | 0.0287 | 0.0287 |
| Loa Loa (eye worm) | carnitine O-palmitoyltransferase I isoform | 0.002 | 0.0138 | 0.0367 |
| Schistosoma mansoni | photoreceptor-specific nuclear receptor related | 0.004 | 0.0385 | 0.0385 |
| Plasmodium falciparum | multidrug resistance protein 1 | 0.0025 | 0.0209 | 0.3649 |
| Echinococcus granulosus | aldehyde dehydrogenase mitochondrial | 0.0073 | 0.0802 | 0.0802 |
| Echinococcus granulosus | DNA apurinic or apyrimidinic site lyase | 0.0023 | 0.0175 | 0.0175 |
| Echinococcus granulosus | ATP binding cassette subfamily B MDR:TAP | 0.0025 | 0.0209 | 0.0209 |
| Onchocerca volvulus | 0.0019 | 0.0126 | 0.0327 | |
| Loa Loa (eye worm) | eukaryotic-type carbonic anhydrase | 0.0147 | 0.1717 | 0.4572 |
| Echinococcus granulosus | nuclear receptor 2DBD gamma | 0.004 | 0.0385 | 0.0385 |
| Entamoeba histolytica | P-glycoprotein-2 | 0.0025 | 0.0209 | 0.5293 |
| Mycobacterium ulcerans | oxidoreductase | 0.0051 | 0.0519 | 0.0558 |
| Onchocerca volvulus | Deterin homolog | 0.0053 | 0.0547 | 0.1782 |
| Entamoeba histolytica | exodeoxyribonuclease III, putative | 0.0023 | 0.0175 | 0.428 |
| Schistosoma mansoni | hypothetical protein | 0.061 | 0.745 | 0.745 |
| Onchocerca volvulus | 0.002 | 0.0138 | 0.0369 | |
| Loa Loa (eye worm) | hypothetical protein | 0.0035 | 0.0323 | 0.0861 |
| Echinococcus multilocularis | tyrosine protein kinase Srms | 0.0041 | 0.0402 | 0.0402 |
| Loa Loa (eye worm) | hypothetical protein | 0.004 | 0.0385 | 0.1025 |
| Brugia malayi | Nuclear hormone receptor family member nhr-40 | 0.004 | 0.0385 | 0.1025 |
| Loa Loa (eye worm) | hypothetical protein | 0.0071 | 0.0779 | 0.2075 |
| Echinococcus multilocularis | nuclear receptor 2DBD gamma | 0.0019 | 0.0126 | 0.0126 |
| Plasmodium vivax | hypothetical protein, conserved | 0.0051 | 0.0519 | 0.6526 |
| Mycobacterium tuberculosis | Probable flavin-containing monoamine oxidase AofH (amine oxidase) (MAO) | 0.0667 | 0.815 | 1 |
| Brugia malayi | MH2 domain containing protein | 0.0126 | 0.1452 | 0.3867 |
| Loa Loa (eye worm) | hypothetical protein | 0.004 | 0.0385 | 0.1025 |
| Trichomonas vaginalis | chromodomain helicase DNA binding protein, putative | 0.0013 | 0.0055 | 0.0315 |
| Mycobacterium leprae | PROBABLE PROTOPORPHYRINOGEN OXIDASE HEMY (PROTOPORPHYRINOGEN-IX OXIDASE) (PROTOPORPHYRINOGENASE) (PPO) | 0.0051 | 0.0519 | 0.6526 |
| Echinococcus multilocularis | aldehyde reductase | 0.0027 | 0.023 | 0.023 |
| Loa Loa (eye worm) | nuclear hormone receptor family member nhr-14 | 0.004 | 0.0385 | 0.1025 |
| Schistosoma mansoni | nuclear hormone receptor nor-1/nor-2 | 0.004 | 0.0385 | 0.0385 |
| Trypanosoma cruzi | apurinic/apyrimidinic endonuclease | 0.0023 | 0.0175 | 0.0854 |
| Brugia malayi | nuclear receptor subfamily 1, group D, member 1, putative | 0.0019 | 0.0126 | 0.0334 |
| Schistosoma mansoni | tyrosine kinase | 0.001 | 0.0021 | 0.0021 |
| Schistosoma mansoni | proto-oncogene tyrosine-protein kinase src | 0.001 | 0.0021 | 0.0021 |
| Echinococcus granulosus | beta LACTamase domain containing family member | 0.0071 | 0.0779 | 0.0779 |
| Mycobacterium ulcerans | protoporphyrinogen oxidase | 0.0051 | 0.0519 | 0.0558 |
| Loa Loa (eye worm) | transcription factor SMAD2 | 0.0126 | 0.1452 | 0.3867 |
| Echinococcus granulosus | carbonic anhydrase | 0.0034 | 0.0309 | 0.0309 |
| Echinococcus granulosus | lysine specific histone demethylase 1A | 0.0051 | 0.0519 | 0.0519 |
| Schistosoma mansoni | zinc finger protein | 0.0019 | 0.0126 | 0.0126 |
| Brugia malayi | nuclear receptor RXR | 0.0019 | 0.0126 | 0.0334 |
| Loa Loa (eye worm) | hypothetical protein | 0.0019 | 0.0126 | 0.0334 |
| Trichomonas vaginalis | penicillin-binding protein, putative | 0.0071 | 0.0779 | 1 |
| Echinococcus multilocularis | GPCR, family 2 | 0.0032 | 0.0287 | 0.0287 |
| Loa Loa (eye worm) | nuclear receptor NHR-67 | 0.0019 | 0.0126 | 0.0334 |
| Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0046 | 0.046 | 0.046 |
| Trichomonas vaginalis | multidrug resistance protein 1, 2, putative | 0.0025 | 0.0209 | 0.2381 |
| Schistosoma mansoni | retinoid-x-receptor (RXR) | 0.0021 | 0.0153 | 0.0153 |
| Trichomonas vaginalis | conserved hypothetical protein | 0.0013 | 0.0055 | 0.0315 |
| Schistosoma mansoni | multidrug resistance protein | 0.0025 | 0.0209 | 0.0209 |
| Echinococcus granulosus | c src tyrosine kinase | 0.001 | 0.0021 | 0.0021 |
| Brugia malayi | latrophilin 2 splice variant baaae | 0.0069 | 0.0743 | 0.198 |
| Echinococcus granulosus | multidrug resistance protein 1 | 0.0025 | 0.0209 | 0.0209 |
| Echinococcus multilocularis | hepatocyte nuclear factor 4 alpha | 0.004 | 0.0385 | 0.0385 |
| Echinococcus granulosus | cdgsh iron sulfur domain containing protein | 0.0575 | 0.702 | 0.702 |
| Echinococcus multilocularis | multidrug resistance protein 1 | 0.0018 | 0.0114 | 0.0114 |
| Trichomonas vaginalis | conserved hypothetical protein | 0.0013 | 0.0055 | 0.0315 |
| Echinococcus granulosus | aldo keto reductase family 1 member B4 | 0.0038 | 0.0368 | 0.0368 |
| Echinococcus granulosus | conserved hypothetical protein | 0.0035 | 0.0323 | 0.0323 |
| Loa Loa (eye worm) | DR-78 | 0.0019 | 0.0126 | 0.0334 |
| Loa Loa (eye worm) | variant SH3 domain-containing protein | 0.0009 | 0.0005 | 0.0013 |
| Mycobacterium tuberculosis | Probable lipase LipD | 0.0071 | 0.0779 | 0.0921 |
| Brugia malayi | SRC-1 | 0.0045 | 0.0457 | 0.1217 |
| Brugia malayi | Uncharacterized hematopoietic stem/progenitor cells protein MDS029 | 0.0245 | 0.2924 | 0.7786 |
| Loa Loa (eye worm) | hypothetical protein | 0.0245 | 0.2924 | 0.7786 |
| Chlamydia trachomatis | protoporphyrinogen oxidase | 0.0051 | 0.0519 | 1 |
| Trichomonas vaginalis | ABC transporter, half transporter, putative | 0.0025 | 0.0209 | 0.2381 |
| Brugia malayi | hypothetical protein | 0.0051 | 0.0519 | 0.1383 |
| Trichomonas vaginalis | multidrug resistance protein 1, 2, putative | 0.0025 | 0.0209 | 0.2381 |
| Echinococcus granulosus | aldo keto reductase family 1 member B4 | 0.0038 | 0.0368 | 0.0368 |
| Echinococcus multilocularis | tyrosine protein kinase lyn lyn a protein tyrosine kinase lymphocyte specific protein tyrosine kinase | 0.0045 | 0.0457 | 0.0457 |
| Brugia malayi | Nuclear hormone receptor family member nhr-3 | 0.004 | 0.0385 | 0.1025 |
| Mycobacterium ulcerans | lipase LipD | 0.0071 | 0.0779 | 0.0856 |
| Trichomonas vaginalis | aldo-keto reductase, putative | 0.0038 | 0.0368 | 0.4498 |
| Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0046 | 0.046 | 0.046 |
| Echinococcus multilocularis | c src tyrosine kinase | 0.001 | 0.0021 | 0.0021 |
| Echinococcus granulosus | aldo keto reductase family 1 member B4 | 0.0038 | 0.0368 | 0.0368 |
| Trichomonas vaginalis | ap endonuclease, putative | 0.0023 | 0.0175 | 0.1925 |
| Schistosoma mansoni | family S12 unassigned peptidase (S12 family) | 0.0071 | 0.0779 | 0.0779 |
| Echinococcus multilocularis | tyrosine protein kinase lyn tyrosine protein kinase blk | 0.0045 | 0.0457 | 0.0457 |
| Loa Loa (eye worm) | hypothetical protein | 0.0025 | 0.0209 | 0.0557 |
| Trichomonas vaginalis | ATP-binding cassette transporter, putative | 0.0025 | 0.0209 | 0.2381 |
| Mycobacterium tuberculosis | Probable lipase LipE | 0.0071 | 0.0779 | 0.0921 |
| Brugia malayi | tailless protein | 0.0019 | 0.0126 | 0.0334 |
| Schistosoma mansoni | growth factor receptor-bound protein | 0.0009 | 0.0005 | 0.0005 |
| Loa Loa (eye worm) | oxidoreductase | 0.0038 | 0.0368 | 0.0979 |
| Schistosoma mansoni | FTZ-F1 nuclear receptor-like protein | 0.004 | 0.0385 | 0.0385 |
| Trypanosoma brucei | hypothetical protein, conserved | 0.0071 | 0.0779 | 0.4438 |
| Schistosoma mansoni | aldehyde dehydrogenase | 0.0073 | 0.0802 | 0.0802 |
| Schistosoma mansoni | carbonic anhydrase-related | 0.0034 | 0.0309 | 0.0309 |
| Loa Loa (eye worm) | oxidoreductase | 0.0038 | 0.0368 | 0.0979 |
| Trichomonas vaginalis | aldo/keto reductase, putative | 0.0038 | 0.0368 | 0.4498 |
| Onchocerca volvulus | 0.0038 | 0.0368 | 0.1163 | |
| Trypanosoma cruzi | hypothetical protein, conserved | 0.002 | 0.0138 | 0.0633 |
| Brugia malayi | SWIRM domain containing protein | 0.0051 | 0.0519 | 0.1383 |
| Trichomonas vaginalis | dihydrodiol dehydrogenase, putative | 0.0038 | 0.0368 | 0.4498 |
| Loa Loa (eye worm) | hypothetical protein | 0.0038 | 0.0368 | 0.0979 |
| Plasmodium falciparum | AP endonuclease (DNA-[apurinic or apyrimidinic site] lyase), putative | 0.0023 | 0.0175 | 0.295 |
| Echinococcus multilocularis | carbonic anhydrase | 0.0034 | 0.0309 | 0.0309 |
| Trypanosoma brucei | carbonic anhydrase-like protein | 0.0147 | 0.1717 | 1 |
| Plasmodium vivax | lysine-specific histone demethylase 1, putative | 0.0051 | 0.0519 | 0.6526 |
| Mycobacterium ulcerans | aldehyde dehydrogenase | 0.0073 | 0.0802 | 0.0882 |
| Trypanosoma brucei | carnitine O-palmitoyltransferase II, putative | 0.002 | 0.0138 | 0.0633 |
| Trichomonas vaginalis | lipid A export ATP-binding/permease protein msba, putative | 0.0025 | 0.0209 | 0.2381 |
| Brugia malayi | steroid hormone receptor | 0.004 | 0.0385 | 0.1025 |
| Echinococcus multilocularis | voltage gated potassium channel subunit | 0.0011 | 0.0031 | 0.0031 |
| Brugia malayi | hypothetical protein | 0.0021 | 0.0153 | 0.0408 |
| Echinococcus granulosus | carbonic anhydrase II | 0.0147 | 0.1717 | 0.1717 |
| Loa Loa (eye worm) | nuclear hormone receptor | 0.0019 | 0.0126 | 0.0334 |
| Trypanosoma cruzi | choline/carnitine O-acyltransferase, putative | 0.0107 | 0.1224 | 0.7078 |
| Schistosoma mansoni | carbonic anhydrase-related | 0.0034 | 0.0309 | 0.0309 |
| Mycobacterium tuberculosis | Possible penicillin-binding protein | 0.0457 | 0.555 | 0.6798 |
| Schistosoma mansoni | inhibitor of apoptosis protein | 0.0053 | 0.0547 | 0.0547 |
| Echinococcus multilocularis | 0.0051 | 0.0519 | 0.0519 | |
| Entamoeba histolytica | P-glyco protein 6, putative | 0.0025 | 0.0209 | 0.5293 |
| Leishmania major | hypothetical protein, conserved | 0.0071 | 0.0779 | 0.4438 |
| Trichomonas vaginalis | conserved hypothetical protein | 0.0013 | 0.0055 | 0.0315 |
| Trichomonas vaginalis | ABC transporter, putative | 0.0025 | 0.0209 | 0.2381 |
| Trichomonas vaginalis | abcb9, putative | 0.0025 | 0.0209 | 0.2381 |
| Trypanosoma cruzi | choline/carnitine O-acyltransferase, putative | 0.002 | 0.0138 | 0.0633 |
| Schistosoma mansoni | hypothetical protein | 0.0034 | 0.0309 | 0.0309 |
| Loa Loa (eye worm) | GTP-binding regulatory protein Gs alpha-S chain | 0.0046 | 0.046 | 0.1225 |
| Loa Loa (eye worm) | TK protein kinase | 0.0041 | 0.0402 | 0.1071 |
| Brugia malayi | RE40412p | 0.0035 | 0.0323 | 0.0861 |
| Echinococcus multilocularis | tyrosine protein kinase Fyn | 0.0041 | 0.0402 | 0.0402 |
| Trichomonas vaginalis | multidrug resistance protein 1, 2, putative | 0.0025 | 0.0209 | 0.2381 |
| Trichomonas vaginalis | multidrug resistance protein 1, 2, putative | 0.0025 | 0.0209 | 0.2381 |
| Loa Loa (eye worm) | hypothetical protein | 0.0071 | 0.0779 | 0.2075 |
| Mycobacterium tuberculosis | Probable conserved lipoprotein | 0.0071 | 0.0779 | 0.0921 |
| Loa Loa (eye worm) | hypothetical protein | 0.0019 | 0.0126 | 0.0334 |
| Echinococcus granulosus | inhibitor of apoptosis protein | 0.0053 | 0.0547 | 0.0547 |
| Echinococcus granulosus | proto oncogene tyrosine protein kinase LCK | 0.0045 | 0.0457 | 0.0457 |
| Brugia malayi | orphan nuclear receptor NR2E1 | 0.0019 | 0.0126 | 0.0334 |
| Echinococcus granulosus | nuclear receptor 2DBD gamma | 0.0019 | 0.0126 | 0.0126 |
| Echinococcus multilocularis | NCK adaptor protein | 0.0009 | 0.0005 | 0.0005 |
| Mycobacterium ulcerans | fusion of enoyl-CoA hydratase, EchA21 and lipase, LipE | 0.0071 | 0.0779 | 0.0856 |
| Echinococcus multilocularis | thyroid hormone receptor alpha | 0.004 | 0.0385 | 0.0385 |
| Echinococcus multilocularis | aldo keto reductase family 1, member B4 | 0.0038 | 0.0368 | 0.0368 |
| Brugia malayi | multidrug resistance protein 3 | 0.0025 | 0.0209 | 0.0557 |
| Schistosoma mansoni | thyroid hormone receptor | 0.004 | 0.0385 | 0.0385 |
| Loa Loa (eye worm) | CXXC zinc finger family protein | 0.0057 | 0.0603 | 0.1607 |
| Onchocerca volvulus | 0.0025 | 0.0209 | 0.0616 | |
| Brugia malayi | hypothetical protein | 0.0021 | 0.0153 | 0.0408 |
| Trypanosoma cruzi | hypothetical protein, conserved | 0.002 | 0.0138 | 0.0633 |
| Loa Loa (eye worm) | hypothetical protein | 0.0021 | 0.0153 | 0.0408 |
| Trichomonas vaginalis | D-aminoacylase, putative | 0.0071 | 0.0779 | 1 |
| Brugia malayi | Choline/Carnitine o-acyltransferase family protein | 0.002 | 0.0138 | 0.0367 |
| Trypanosoma brucei | prostaglandin f synthase | 0.0038 | 0.0368 | 0.1996 |
| Loa Loa (eye worm) | hypothetical protein | 0.0071 | 0.0779 | 0.2075 |
| Brugia malayi | GTP-binding regulatory protein Gs alpha-S chain, putative | 0.0046 | 0.046 | 0.1225 |
| Onchocerca volvulus | 0.0057 | 0.0603 | 0.1979 | |
| Brugia malayi | ecdysone receptor | 0.0019 | 0.0126 | 0.0334 |
| Echinococcus granulosus | hypothetical protein | 0.0038 | 0.0368 | 0.0368 |
| Plasmodium vivax | hypothetical protein, conserved | 0.0051 | 0.0519 | 0.6526 |
| Echinococcus multilocularis | FTZ F1 nuclear receptor protein | 0.004 | 0.0385 | 0.0385 |
| Leishmania major | hypothetical protein, unknown function | 0.0035 | 0.0323 | 0.1734 |
| Brugia malayi | CXXC zinc finger family protein | 0.0057 | 0.0603 | 0.1607 |
| Echinococcus multilocularis | DNA (apurinic or apyrimidinic site) lyase | 0.0023 | 0.0175 | 0.0175 |
| Loa Loa (eye worm) | hypothetical protein | 0.0019 | 0.0126 | 0.0334 |
| Schistosoma mansoni | retinoic acid receptor RXR | 0.004 | 0.0385 | 0.0385 |
| Loa Loa (eye worm) | pigment dispersing factor receptor c | 0.01 | 0.1137 | 0.3027 |
| Trypanosoma cruzi | aldo/keto reductase, putative | 0.0038 | 0.0368 | 0.1996 |
| Mycobacterium tuberculosis | Conserved protein | 0.0071 | 0.0779 | 0.0921 |
| Trichomonas vaginalis | esterase, putative | 0.0071 | 0.0779 | 1 |
| Trichomonas vaginalis | chromodomain helicase DNA binding protein, putative | 0.0013 | 0.0055 | 0.0315 |
| Trichomonas vaginalis | conserved hypothetical protein | 0.0013 | 0.0055 | 0.0315 |
| Brugia malayi | nuclear receptor NHR-67 | 0.0019 | 0.0126 | 0.0334 |
| Schistosoma mansoni | aldo-keto reductase | 0.0038 | 0.0368 | 0.0368 |
| Entamoeba histolytica | aldose reductase, putative | 0.0038 | 0.0368 | 1 |
| Brugia malayi | Nuclear hormone receptor E75 | 0.0019 | 0.0126 | 0.0334 |
| Schistosoma mansoni | cpg binding protein | 0.0061 | 0.0644 | 0.0644 |
| Plasmodium vivax | hypothetical protein, conserved | 0.0071 | 0.0779 | 1 |
| Loa Loa (eye worm) | hypothetical protein | 0.0025 | 0.0206 | 0.0548 |
| Schistosoma mansoni | carbonic anhydrase | 0.0034 | 0.0309 | 0.0309 |
| Loa Loa (eye worm) | hypothetical protein | 0.0051 | 0.0519 | 0.1383 |
| Schistosoma mansoni | carbonic anhydrase II (carbonate dehydratase II) | 0.0147 | 0.1717 | 0.1717 |
| Echinococcus multilocularis | beta LACTamase domain containing family member | 0.0071 | 0.0779 | 0.0779 |
| Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0046 | 0.046 | 0.046 |
| Trichomonas vaginalis | lipid A export ATP-binding/permease protein msba, putative | 0.0025 | 0.0209 | 0.2381 |
| Mycobacterium ulcerans | flavin-containing monoamine oxidase AofH | 0.0717 | 0.8775 | 1 |
| Loa Loa (eye worm) | eukaryotic-type carbonic anhydrase | 0.0034 | 0.0309 | 0.0824 |
| Trichomonas vaginalis | lipid A export ATP-binding/permease protein msba, putative | 0.0025 | 0.0209 | 0.2381 |
| Echinococcus granulosus | voltage gated potassium channel subunit | 0.0011 | 0.0031 | 0.0031 |
| Echinococcus multilocularis | FTZ F1 alpha | 0.004 | 0.0385 | 0.0385 |
| Loa Loa (eye worm) | nuclear hormone receptor family member nhr-41 | 0.004 | 0.0385 | 0.1025 |
| Echinococcus granulosus | aldo keto reductase family 1 member B4 | 0.0038 | 0.0368 | 0.0368 |
| Loa Loa (eye worm) | hypothetical protein | 0.0051 | 0.0519 | 0.1383 |
| Schistosoma mansoni | inhibitor of apoptosis (iap) domain family member | 0.0053 | 0.0547 | 0.0547 |
| Echinococcus granulosus | hepatocyte nuclear factor 4 alpha | 0.004 | 0.0385 | 0.0385 |
| Onchocerca volvulus | 0.0038 | 0.0368 | 0.1163 | |
| Echinococcus granulosus | aldo keto reductase family 1 member B4 | 0.0038 | 0.0368 | 0.0368 |
| Echinococcus multilocularis | carnitine O palmitoyltransferase 2 | 0.002 | 0.0138 | 0.0138 |
| Plasmodium falciparum | CDGSH iron-sulfur domain-containing protein, putative | 0.0035 | 0.0323 | 0.5988 |
| Entamoeba histolytica | P-glycoprotein 5, putative | 0.0025 | 0.0209 | 0.5293 |
| Trichomonas vaginalis | lipid A export ATP-binding/permease protein msba, putative | 0.0025 | 0.0209 | 0.2381 |
| Schistosoma mansoni | ap endonuclease | 0.0023 | 0.0175 | 0.0175 |
| Mycobacterium leprae | conserved hypothetical protein | 0.0071 | 0.0779 | 1 |
| Trichomonas vaginalis | aldo/keto reductase, putative | 0.0038 | 0.0368 | 0.4498 |
| Schistosoma mansoni | hepatocyte nuclear factor 4-alpha (hnf-4-alpha) | 0.0019 | 0.0126 | 0.0126 |
| Onchocerca volvulus | Steroid hormone receptor family member cnr14 homolog | 0.004 | 0.0385 | 0.1224 |
| Trypanosoma cruzi | hypothetical protein, conserved | 0.0071 | 0.0779 | 0.4438 |
| Echinococcus multilocularis | histone lysine N methyltransferase MLL3 | 0.0014 | 0.007 | 0.007 |
| Leishmania major | p-glycoprotein | 0.0025 | 0.0209 | 0.1057 |
| Trichomonas vaginalis | lipid A export ATP-binding/permease protein msba, putative | 0.0025 | 0.0209 | 0.2381 |
| Echinococcus granulosus | cpg binding protein | 0.0061 | 0.0644 | 0.0644 |
| Echinococcus multilocularis | multidrug resistance protein 1 | 0.0025 | 0.0209 | 0.0209 |
| Onchocerca volvulus | 0.002 | 0.0138 | 0.0369 | |
| Echinococcus multilocularis | ATP binding cassette subfamily B (MDR:TAP) | 0.0025 | 0.0209 | 0.0209 |
| Plasmodium falciparum | carbonic anhydrase | 0.0034 | 0.0309 | 0.5701 |
| Trichomonas vaginalis | conserved hypothetical protein | 0.0013 | 0.0055 | 0.0315 |
| Echinococcus granulosus | tyrosine protein kinase Src42A | 0.0045 | 0.0457 | 0.0457 |
| Loa Loa (eye worm) | hypothetical protein | 0.004 | 0.0385 | 0.1025 |
| Schistosoma mansoni | nuclear receptor nhr-48 | 0.0019 | 0.0126 | 0.0126 |
| Entamoeba histolytica | P-glycoprotein-2, putative | 0.0025 | 0.0209 | 0.5293 |
| Loa Loa (eye worm) | hypothetical protein | 0.0019 | 0.0126 | 0.0334 |
| Schistosoma mansoni | hypothetical protein | 0.0032 | 0.0287 | 0.0287 |
| Trichomonas vaginalis | chromodomain helicase DNA binding protein, putative | 0.0013 | 0.0055 | 0.0315 |
| Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0046 | 0.046 | 0.046 |
| Trichomonas vaginalis | dihydrodiol dehydrogenase, putative | 0.0038 | 0.0368 | 0.4498 |
| Echinococcus multilocularis | tyrosine protein kinase Fyn | 0.0045 | 0.0457 | 0.0457 |
Activities
| Activity type | Activity value | Assay description | Source | Reference |
|---|---|---|---|---|
| %max (binding) | = 80 % | Partial agonist activity at human PPARgamma-LBD/Gal4 DNA binding domain by transactivation assay relative to darglitazone | ChEMBL. | 23265881 |
| Activity (binding) | Binding affinity to afadin- and alpha-actinin-binding protein in Sprague-Dawley rat heart homogenate after 15 mins by chromatographic analysis | ChEMBL. | 22970990 | |
| Activity (binding) | Binding affinity to mouse trace amine-associated receptor 7b by chromatographic analysis | ChEMBL. | 22970990 | |
| Activity (binding) | Binding affinity to hemopexin precursor in Sprague-Dawley rat heart homogenate after 15 mins by chromatographic analysis | ChEMBL. | 22970990 | |
| Activity (functional) | Partial agonist activity at human PPARgamma-LBD expressed in HEK293T cells assessed as induction of receptor transactivation at 10 uM after 24 hrs by luciferase reporter gene assay | ChEMBL. | 21030263 | |
| Activity (functional) | Antihyperglycemic activity in C57BL/Ks db/db mouse assessed as reduction of blood glucose level at 10 mg/kg measured from day 6 to day 14 | ChEMBL. | No reference | |
| Activity (binding) | Binding affinity to trace amine-associated receptor 7b in Sprague-Dawley rat heart homogenate after 15 mins by chromatographic analysis | ChEMBL. | 22970990 | |
| Activity (binding) | Binding affinity to focal adhesion kinase 2 in Sprague-Dawley rat heart homogenate after 15 mins by chromatographic analysis | ChEMBL. | 22970990 | |
| Activity (binding) | Transactivation of human PPARalpha LBD expressed in african green monkey Cos7 cells co-transfected with fused GAL4-DBD at 10 uM after 14 hrs by Dual-Glo Luciferase reporter gene assay | ChEMBL. | 20307981 | |
| Activity (binding) | Transactivation of PPAR-gamma (unknown origin) expressed in HEK293 cells at 10 uM after 24 hrs by luciferase reporter gene assay | ChEMBL. | 24890090 | |
| Activity (binding) | Binding affinity to mitochondrial ATP synthase alpha chain in Sprague-Dawley rat heart homogenate after 15 mins by chromatographic analysis | ChEMBL. | 22970990 | |
| Activity (binding) | Binding affinity to mitochondrial long-chain specific acyl-CoA dehydrogenase in Sprague-Dawley rat heart homogenate after 15 mins by chromatographic analysis relative to rosiglitazone | ChEMBL. | 22970990 | |
| Activity (binding) | Binding affinity to glyceraldehyde 3-phosphate dehydrogenase in Sprague-Dawley rat heart homogenate after 15 mins by chromatographic analysis | ChEMBL. | 22970990 | |
| Activity (binding) | Binding affinity to RasGTPase-activating protein SynGAP in Sprague-Dawley rat heart homogenate after 15 mins by chromatographic analysis relative to pioglitazone | ChEMBL. | 22970990 | |
| Activity (binding) | Binding affinity to mouse importin-7 by chromatographic analysis | ChEMBL. | 22970990 | |
| Activity (binding) | Transactivation of GAL4-fused human PPARdelta ligand binding domain transfected in african green monkey COS7 cells at 10 uM by luciferase reporter gene assay relative to L-165041 | ChEMBL. | 23130964 | |
| Activity (binding) | Binding affinity to mouse cardiotrophin-like cytokine factor 1 by chromatographic analysis | ChEMBL. | 22970990 | |
| Activity (binding) | Binding affinity to Huntingtin-associated protein-interacting protein in Sprague-Dawley rat heart homogenate after 15 mins by chromatographic analysis | ChEMBL. | 22970990 | |
| Activity (binding) | Binding affinity to PX domain-containing protein kinase-like protein in Sprague-Dawley rat heart homogenate after 15 mins by chromatographic analysis relative to pioglitazone | ChEMBL. | 22970990 | |
| Activity (binding) | Binding affinity to creatine kinase B-type in Sprague-Dawley rat heart homogenate after 15 mins by chromatographic analysis | ChEMBL. | 22970990 | |
| Activity (binding) | Agonist activity at human PPAR-gamma expressed in HEK293 cells at 5 uM after 18 hrs by luciferase reporter gene assay in presence of T0070907 | ChEMBL. | 24597776 | |
| Activity (binding) | Binding affinity to mouse mitochondrial dihydrolipoyl dehydrogenase by chromatographic analysis relative to rosiglitazone | ChEMBL. | 22970990 | |
| Activity (binding) | Activation of peroxisome proliferator-activated receptor gamma in reporter gene assay: most active | ChEMBL. | 15745794 | |
| Activity (binding) | Binding affinity to mouse protein kinase C and casein kinase substrate in neurons protein 2 by chromatographic analysis | ChEMBL. | 22970990 | |
| Activity (binding) | Binding affinity to L-lactate dehydrogenase B chain in Sprague-Dawley rat heart homogenate after 15 mins by chromatographic analysis relative to rosiglitazone | ChEMBL. | 22970990 | |
| Activity (ADMET) | Toxicity in db/db mouse assessed as increase of body weight at 41 mg/kg administered with chow diet ad for 14 days | ChEMBL. | 21130649 | |
| Activity (binding) | Binding affinity to mouse norrin precursor by chromatographic analysis | ChEMBL. | 22970990 | |
| Activity (binding) | Binding affinity to mouse membrane transport protein XK by chromatographic analysis relative to pioglitazone | ChEMBL. | 22970990 | |
| Activity (binding) | Binding affinity to neuronal acetylcholine receptor subunit alpha-10 in Sprague-Dawley rat heart homogenate after 15 mins by chromatographic analysis | ChEMBL. | 22970990 | |
| Activity (functional) | Antidiabetic activity in db/db mouse assessed as reduction of blood glucose level at 41 mg/kg administered with chow diet ad for 14 days | ChEMBL. | 21130649 | |
| Activity (binding) | Binding affinity to mitochondrial ATP synthase beta chain in Sprague-Dawley rat heart homogenate after 15 mins by chromatographic analysis | ChEMBL. | 22970990 | |
| Activity (binding) | Binding affinity to mitochondrial aspartate aminotransferase in Sprague-Dawley rat heart homogenate after 15 mins by chromatographic analysis | ChEMBL. | 22970990 | |
| Activity (functional) | Partial agonist activity at human PPARgamma-LBD expressed in HEK293T cells assessed as induction of receptor transactivation at 1 uM after 24 hrs by luciferase reporter gene assay | ChEMBL. | 21030263 | |
| Activity (functional) | Agonist activity at PPARgamma expressed in HEK293 cells assessed as induction of receptor interaction with steroid receptor coactivator-1 by EYFP based reporter gene assay | ChEMBL. | 16680159 | |
| Activity (binding) | Transactivation of GAL4-fused human PPARalpha ligand binding domain transfected in african green monkey COS7 cells at 10 uM by luciferase reporter gene assay relative to GW7647 | ChEMBL. | 23130964 | |
| Activity (binding) | Binding affinity to mouse mitochondrial 2-oxoglutarate dehydrogenase E1 component by chromatographic analysis | ChEMBL. | 22970990 | |
| Activity (functional) | Agonist activity at PPARgamma expressed in HEK293 cells assessed as induction of receptor interaction with retinoid X-receptor alpha by EYFP based reporter gene assay | ChEMBL. | 16680159 | |
| Activity (functional) | Antidiabetic activity in diet-induced obesity mouse assessed as reduction in fasting glucose level at 30 mg/kg, po | ChEMBL. | 23414800 | |
| Activity (binding) | Binding affinity to Phosphoglycerate kinase 1 in Sprague-Dawley rat heart homogenate after 15 mins by chromatographic analysis | ChEMBL. | 22970990 | |
| Activity (ADMET) | Toxicity in db/db mouse assessed as effect on food intake at 41 mg/kg administered with chow diet ad for 14 days | ChEMBL. | 21130649 | |
| Activity (binding) | Binding affinity to 26S proteasome non-ATPase regulatory subunit 1 in Sprague-Dawley rat heart homogenate after 15 mins by chromatographic analysis | ChEMBL. | 22970990 | |
| Activity (binding) | Binding affinity to sodium-dependent multivitamin transporter in Sprague-Dawley rat heart homogenate after 15 mins by chromatographic analysis | ChEMBL. | 22970990 | |
| Activity | Toxicity in diet-induced obese mouse assessed as change in body weight at 10 mg/kg, po qd administered daily via gavage for 28 days | LITERATURE. | 28105274 | |
| Activity (binding) | Binding affinity to mouse chloride channel protein 6 after 15 mins by chromatographic analysis | ChEMBL. | 22970990 | |
| Activity (binding) | Binding affinity to mouse interleukin-12 beta chain precursor by chromatographic analysis | ChEMBL. | 22970990 | |
| Activity (ADMET) | Clinically relevant inhibitors of human liver microsomal P450 enzymes, isoform CYP2C8 | ChEMBL. | No reference | |
| Activity (binding) | = 6.9 | Activation of PPAR gamma at 5 uM in Cos-7 cell reporter gene assay with 5%FBS | ChEMBL. | 15664804 |
| Activity (binding) | 0 | Activation of peroxisome proliferator-activated receptor gamma in reporter gene assay: most active | ChEMBL. | 15745794 |
| Activity (binding) | = 6.9 | Activation of PPAR gamma at 5 uM in Cos-7 cell reporter gene assay with 5%FBS | ChEMBL. | 15664804 |
| Activity (functional) | = 10 % | Insulin-releasing activity in HIT-T15 cells in the presence of 16.7mM glucose at 10 microM expressed as percent activity of nateglinide | ChEMBL. | 11078199 |
| Activity (ADMET) | = 17 % | Toxicity in db/db mouse assessed as body weight gain at 30 mg/kg/day, po administered daily for 14 days relative to control | ChEMBL. | 21377875 |
| Activity (functional) | = 50 % | Antihyperglycemic activity in db/db mouse assessed as reduction in blood glucose level at 75 mg/kg, po administered once daily for 11 days | ChEMBL. | 19507861 |
| Activity (functional) | = 53 % | Antidiabetic activity in C57BLKS/J-m+/+Leprdb db/db mouse assessed as reduction in plasma glucose levels at 10 mg/kg, po once daily for 11 days relative to control | ChEMBL. | 19530681 |
| Activity (functional) | = 65 % | Antidiabetic activity in C57BLKS/J-m+/+Leprdb db/db mouse assessed as reduction in plasma triglyceride levels at 10 mg/kg, po once daily for 11 days relative to control | ChEMBL. | 19530681 |
| Activity (binding) | = 71.94 % | Agonist activity at PPARgamma (unknown origin) expressed in HEK293 cells assessed as receptor transactivation at 10 uM by PPRE-driven luciferase reporter gene assay | ChEMBL. | 25255433 |
| Activity (functional) | = 100 % | Compound was tested for insulin-sensitizing activity by measuring triglyceride accumlation from insulin regulated differentiation of 3T3-L1 cells at 10 microM expressed as percent activity of pioglitazone | ChEMBL. | 11078199 |
| Activity (functional) | = 100 % | Insulin-sensitizing activity; triglyceride accumlation from insulin regulated differentiation of 3T3-L1 cells at 1 microM expressed as percent activity of pioglitazone | ChEMBL. | 11078199 |
| Activity (binding) | = 100 % | Transactivation of human PPARgamma LBD expressed in african green monkey Cos7 cells co-transfected with fused GAL4-DBD after 14 hrs by Dual-Glo Luciferase reporter gene assay relative to pioglitazone | ChEMBL. | 20307981 |
| Activity (binding) | = 100 % | Activation of Gal4-tagged human PPARgamma expressed in CHO cells by luciferase reporter gene assay relative to pioglitazone | ChEMBL. | 20656494 |
| Activity (functional) | = 100 % | Partial agonist activity at human PPARgamma expressed in CHO cells co-transfected with Gal4-responsive luciferase reporter plasmid after 24 hrs by transactivation assay relative to pioglitazone | ChEMBL. | 21377875 |
| Activity (functional) | = 100 % | Compound was tested for insulin-sensitizing activity by measuring triglyceride accumlation from insulin regulated differentiation of 3T3-L1 cells at 10 microM expressed as percent activity of pioglitazone | ChEMBL. | 11078199 |
| Activity (functional) | = 100 % | Insulin-sensitizing activity; triglyceride accumlation from insulin regulated differentiation of 3T3-L1 cells at 1 microM expressed as percent activity of pioglitazone | ChEMBL. | 11078199 |
| Activity (binding) | = 100 % | Transactivation of GAL4-fused human PPARgamma ligand binding domain expressed in African green monkey COS7 cells at 10 uM after 42 hrs by dual luciferase reporter gene assay | LITERATURE. | 27560282 |
| Activity (ADMET) | = 15.5 g | In vivo body weight gain was observed in db/db mouse 4 weeks after oral administration (once daily) of 100 mg/kg of compound; (n=6) | ChEMBL. | 15664804 |
| Activity (ADMET) | = 96.6 g | In vivo body weight gain was observed in ZDF rats 4 weeks after oral administration (once daily) of 30 mg/kg of compound; (n=6) | ChEMBL. | 15664804 |
| Activity (ADMET) | = 0.2 mg/dl | Toxicity against KKAy mouse assessed as creatinine level at 10 mg/kg/day, po for 14 days (Rvb = 0.2 mg/dl) | ChEMBL. | 23391145 |
| Activity (functional) | = 230 mg/dl | Antidiabetic activity in mouse 3T3L1 cells assessed as decrease in glucose consumption from cell culture medium using 450 mg/dL D-glucose at 30 ug/mL after 24 hrs (Rvb = 310 +/- 4 mg/dl) | ChEMBL. | 22608392 |
| Activity (functional) | = 5.51 mmol/L | Glucose consumption in differentiated mouse 3T3L1 cells in low-glucose medium at 50 ug/ml after 24 hrs by glucose-oxidase method (Rvb =2.41 +/- 0.22 mmol/L) | ChEMBL. | 21515060 |
| Activity (functional) | = 6.75 mmol/L | Glucose consumption in differentiated mouse 3T3L1 cells in low-glucose medium at 100 ug/ml after 24 hrs by glucose-oxidase method (Rvb =2.35 +/- 0.19 mmol/L) | ChEMBL. | 21515060 |
| Activity (functional) | = 7.36 mmol/L | Glucose consumption in differentiated mouse 3T3L1 cells in high-glucose medium at 50 ug/ml after 24 hrs by glucose-oxidase method (Rvb =3.06 +/- 0.29 mmol/L) | ChEMBL. | 21515060 |
| Activity (functional) | = 8.15 mmol/L | Glucose consumption in differentiated mouse 3T3L1 cells in high-glucose medium at 100 ug/ml after 24 hrs by glucose-oxidase method (Rvb =3.12 +/- 0.32 mmol/L) | ChEMBL. | 21515060 |
| AUC (ADMET) | = 1753075 ng min | Area under plasma concentration time curve after oral administration of the compound at a dose 2.2 mg/kg | ChEMBL. | 11831892 |
| AUC (ADMET) | = 180 uM.hr | AUC in C57BLKS/J-m+/+Leprdb db/db mouse at 10 mg/kg, po once daily for 11 days | ChEMBL. | 19530681 |
| AUC (ADMET) | = 205 uM.hr | AUC in db/db mouse at 75 mg/kg, po administered once daily for 11 days | ChEMBL. | 19507861 |
| AUC ED50 (ADMET) | = 12.09 mg kg-1 | Area under blood glucose time curve after OGTT on the 9th day of treatment | ChEMBL. | 11831892 |
| Average food intake (functional) | = 6.34 g mouse-1 day-1 | Average food intake of the diabetic KK-Ay mice was measured from total intake amount/days/number of mice | ChEMBL. | 14643306 |
| Average food intake (functional) | = 6.34 g mouse-1 day-1 | Average food intake of the diabetic KK-Ay mice was measured from total intake amount/days/number of mice | ChEMBL. | 14643306 |
| Average sample intake (functional) | = 23 mg kg-1 day-1 | Average sample intake of the diabetic KK-Ay mice was measured as average food intake/average body weight of mice | ChEMBL. | 14643306 |
| Average sample intake (functional) | = 23 mg kg-1 day-1 | Average sample intake of the diabetic KK-Ay mice was measured as average food intake/average body weight of mice | ChEMBL. | 14643306 |
| Blood glucose (functional) | = 191 mg dl-1 | Blood glucose level of the diabetic KK-Ay mice on day 4 was measured | ChEMBL. | 14643306 |
| Blood glucose (functional) | = 191 mg dl-1 | Blood glucose level of the diabetic KK-Ay mice on day 4 was measured | ChEMBL. | 14643306 |
| Blood glucose (functional) | = 486 mg dl-1 | Blood glucose level of the diabetic KK-Ay mice on day 0 was measured | ChEMBL. | 14643306 |
| Blood glucose (functional) | = 486 mg dl-1 | Blood glucose level of the diabetic KK-Ay mice on day 0 was measured | ChEMBL. | 14643306 |
| Body weight (functional) | = 52.5 g | Body weight of the fasted diabetic KK-Ay mice on day 10 was measured | ChEMBL. | 14643306 |
| Body weight (functional) | = 52.5 g | Body weight of the fasted diabetic KK-Ay mice on day 10 was measured | ChEMBL. | 14643306 |
| Body weight (functional) | = 53.6 g | Body weight of the non-fasted diabetic KK-Ay mice on day 4 was measured | ChEMBL. | 14643306 |
| Body weight (functional) | = 53.6 g | Body weight of the non-fasted diabetic KK-Ay mice on day 4 was measured | ChEMBL. | 14643306 |
| Body weight (functional) | = 55.1 g | Body weight of the non-fasted diabetic KK-Ay mice on day 0 was measured | ChEMBL. | 14643306 |
| Body weight (functional) | = 55.1 g | Body weight of the non-fasted diabetic KK-Ay mice on day 0 was measured | ChEMBL. | 14643306 |
| Body weight (functional) | = 55.8 g | Body weight of the non-fasted diabetic KK-Ay mice on day 7 was measured | ChEMBL. | 14643306 |
| Body weight (functional) | = 55.8 g | Body weight of the non-fasted diabetic KK-Ay mice on day 7 was measured | ChEMBL. | 14643306 |
| Change (functional) | = 42 % | Blood glucose lowering activity in hyperglycemic kk mice. | ChEMBL. | 10714503 |
| CL (ADMET) | = 1.4 ml min-1 kg-1 | Clearance after oral administration | ChEMBL. | 11831892 |
| Cmax (ADMET) | = 4664.99999999998 ng ml-1 | Maximum plasma concentration after oral administration of the compound at a dose 2.2 mg/kg | ChEMBL. | 11831892 |
| Decrease in blood glucose (functional) | = 14 % | Antihyperglycemic activity was determined in obese (ob/ob) mice by po administration at a dose of 10 mg/kg | ChEMBL. | 10098657 |
| Decrease in blood glucose (functional) | = 14 % | Antihyperglycemic activity was determined in obese (ob/ob) mice by po administration at a dose of 10 mg/kg | ChEMBL. | 10098657 |
| Delta Tm (binding) | = 2.5 degrees C | Inhibition of human recombinant soluble MAO-B assessed as change in melting temperature at 100 uM after 20 mins by SYPRO orange staining-based fluorescence assay | ChEMBL. | 25600407 |
| Displacement (binding) | = 90 % | Displacement of [3H]-BRL 49653 from glutathione S-transferase-Peroxisome proliferator activated receptor gamma ligand binding domain in bacterial extracts | ChEMBL. | 8576907 |
| Displacement (binding) | = 90 % | Displacement of [3H]-BRL 49653 from glutathione S-transferase-Peroxisome proliferator activated receptor gamma ligand binding domain in bacterial extracts | ChEMBL. | 8576907 |
| EC50 (binding) | Transactivation of human GAL4-fused PPARalpha ligand binding domain transfected in HEK293 cells after 18 hrs by dual luciferase reporter gene assay | ChEMBL. | 23102891 | |
| EC50 (binding) | Transactivation of human PPARdelta expressed in African green monkey COS7 cells incubated overnight by dual-glo luciferase reporter gene assay | ChEMBL. | 26595749 | |
| EC50 (binding) | Transactivation of GAL4-fused human PPARdelta ligand binding domain transfected in african green monkey COS7 cells by luciferase reporter gene assay | ChEMBL. | 23130964 | |
| EC50 (binding) | Agonist activity at GAL4-tagged human PPARalpha ligand binding domain expressed in HepG2 cells assessed as transactivation at 5 to 10 uM after 20 hrs by beta-galactosidase reporter gene assay | ChEMBL. | 22341573 | |
| EC50 (binding) | Transactivation of GAL4-fused human PPARalpha ligand binding domain transfected in african green monkey COS7 cells by luciferase reporter gene assay | ChEMBL. | 23130964 | |
| EC50 (functional) | Partial agonist activity at human PPARalpha expressed in CHO cells co-transfected with Gal4-responsive luciferase reporter plasmid after 24 hrs by transactivation assay | ChEMBL. | 21377875 | |
| EC50 (binding) | Transactivation of human PPARalpha expressed in African green monkey COS7 cells incubated overnight by dual-glo luciferase reporter gene assay | ChEMBL. | 26595749 | |
| EC50 (functional) | = -6.23 | Activation of peroxisome proliferator activated receptor gamma measured by induction of 50% of maximum alkaline phosphatase activity, transfection assay in CV-1 cells | ChEMBL. | 9836620 |
| EC50 (functional) | = -6.23 | Transcriptional activation of peroxisome proliferator activated receptor gamma | ChEMBL. | 10612594 |
| EC50 (binding) | = 3.09 | Agonist activity at FFAR1 (unknown origin) assessed as increase in ERK1/2 MAP kinase phosphorylation | ChEMBL. | 25441945 |
| EC50 (functional) | = 0.00000016 M | Effective concentration for 50% enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells | ChEMBL. | 9599241 |
| EC50 (functional) | = 1.6 M | Effective concentration for 50% enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells | ChEMBL. | 9599241 |
| EC50 (functional) | = 580 nM | Maximal reporter activity against human Peroxisome proliferator activated receptor gamma Gal4 chimeric in transiently transfected CV-1 cells by functional assay. | ChEMBL. | 11720854 |
| EC50 (functional) | = 580 nM | Maximal reporter activity against human Peroxisome proliferator activated receptor gamma Gal4 chimeric in transiently transfected CV-1 cells by functional assay. | ChEMBL. | 11720854 |
| EC50 (binding) | = 1280 nM | Partial agonist activity at human PPARgamma-LBD/Gal4 DNA binding domain by transactivation assay | ChEMBL. | 21557540 |
| EC50 (binding) | = 1280 nM | Partial agonist activity at human PPARgamma-LBD/Gal4 DNA binding domain by transactivation assay | ChEMBL. | 23265881 |
| EC50 (functional) | uM | Agonist activity for Human PPAR alpha receptor in transcriptional activation assay; IA means inactive at 10 uM | ChEMBL. | 10691680 |
| EC50 (functional) | uM | In vitro transcriptional activation of peroxisome proliferator activated delta-receptor (PPAR) expressed in CV-1 cells; Inactive | ChEMBL. | 8576907 |
| EC50 (functional) | uM | Agonist activity for murine PPAR alpha receptor in transcriptional activation assay; IA means inactive at 10 uM | ChEMBL. | 10691680 |
| EC50 (functional) | uM | Agonist activity for murine PPAR delta receptor in transcriptional activation assay; IA means inactive at 10 uM | ChEMBL. | 10691680 |
| EC50 (functional) | uM | In vitro transcriptional activation of peroxisome proliferator activated alpha-receptor (PPAR) expressed in CV-1 cells; Inactive | ChEMBL. | 8576907 |
| EC50 (functional) | uM | Agonist activity for Human PPAR delta receptor in transcriptional activation assay; IA means inactive at 10 uM | ChEMBL. | 10691680 |
| EC50 (functional) | 0 uM | Agonist activity for murine PPAR alpha receptor in transcriptional activation assay; IA means inactive at 10 uM | ChEMBL. | 10691680 |
| EC50 (functional) | 0 uM | Agonist activity for murine PPAR delta receptor in transcriptional activation assay; IA means inactive at 10 uM | ChEMBL. | 10691680 |
| EC50 (functional) | 0 uM | Agonist activity for Human PPAR alpha receptor in transcriptional activation assay; IA means inactive at 10 uM | ChEMBL. | 10691680 |
| EC50 (functional) | 0 uM | Agonist activity for Human PPAR delta receptor in transcriptional activation assay; IA means inactive at 10 uM | ChEMBL. | 10691680 |
| EC50 (functional) | 0 uM | In vitro transcriptional activation of peroxisome proliferator activated alpha-receptor (PPAR) expressed in CV-1 cells; Inactive | ChEMBL. | 8576907 |
| EC50 (functional) | 0 uM | In vitro transcriptional activation of peroxisome proliferator activated delta-receptor (PPAR) expressed in CV-1 cells; Inactive | ChEMBL. | 8576907 |
| EC50 (binding) | 0 uM | In vitro transactivation of human Peroxisome proliferator activated receptor delta (hPPARdelta); Not calculated for transactivation <25% at 30 uM | ChEMBL. | 14584939 |
| EC50 (functional) | = 0.088 uM | Agonist activity at PPARgamma assessed as transcriptional activation | ChEMBL. | 20219371 |
| EC50 (binding) | = 0.14 uM | Activation of Gal4-tagged human PPARgamma expressed in CHO cells by luciferase reporter gene assay | ChEMBL. | 20656494 |
| EC50 (binding) | = 0.2 uM | Transactivation of GAL4-fused human PPARgamma ligand binding domain transfected in african green monkey COS7 cells by luciferase reporter gene assay | ChEMBL. | 23130964 |
| EC50 (binding) | = 0.2 uM | Transactivation of human PPARgamma expressed in African green monkey COS7 cells incubated overnight by dual-glo luciferase reporter gene assay | ChEMBL. | 26595749 |
| EC50 (binding) | = 0.21 uM | Agonist activity at human PPARgamma expressed in HEK293 cells incubated for 18 hrs by luciferase reporter gene assay | ChEMBL. | 25333853 |
| EC50 (binding) | = 0.3 uM | Transactivation of human PPARgamma LBD expressed in african green monkey Cos7 cells co-transfected with fused GAL4-DBD after 14 hrs by Dual-Glo Luciferase reporter gene assay | ChEMBL. | 20307981 |
| EC50 (binding) | = 0.3 uM | Modulation of human PPARgamma-LBD expressed in african green monkey COS7 cells co-transfected with Gal4 assessed as activation of transactivation activity by luciferase assay | ChEMBL. | 21873070 |
| EC50 (binding) | = 0.32 uM | Transactivation at Gal4 fused PPARgamma LBD (unknown origin) expressed in African green monkey COS7 cells after 42 hrs by luciferase assay | LITERATURE. | 27569195 |
| EC50 (binding) | = 0.39 uM | Agonist activity at human PPARgamma ligand binding domain expressed in COS-1 cells co-transfected with Gal4 by luciferase reporter gene assay | ChEMBL. | 21130649 |
| EC50 (functional) | = 0.39 uM | Partial agonist activity at human PPARgamma expressed in CHO cells co-transfected with Gal4-responsive luciferase reporter plasmid after 24 hrs by transactivation assay | ChEMBL. | 21377875 |
| EC50 (binding) | = 0.5 uM | Transactivation of GAL4-fused human PPARgamma ligand binding domain expressed in African green monkey COS7 cells after 42 hrs by dual luciferase reporter gene assay | LITERATURE. | 27560282 |
| EC50 (functional) | = 0.55 uM | Agonist activity for murine PPAR gamma receptor in transcriptional activation assay | ChEMBL. | 10691680 |
| EC50 (functional) | = 0.55 uM | Transactivation of PPARgamma in CV1 cells | ChEMBL. | 16821769 |
| EC50 (functional) | = 0.55 uM | Agonist activity for murine PPAR gamma receptor in transcriptional activation assay | ChEMBL. | 10691680 |
| EC50 (functional) | = 0.55 uM | Transactivation of PPARgamma in CV1 cells | ChEMBL. | 16821769 |
| EC50 (binding) | = 0.57 uM | Agonist activity at GAL4-tagged human PPARgamma ligand binding domain expressed in HepG2 cells assessed as transactivation after 20 hrs by beta-galactosidase reporter gene assay | ChEMBL. | 22341573 |
| EC50 (functional) | = 0.58 uM | Agonist activity for Human PPAR gamma receptor in transcriptional activation assay | ChEMBL. | 10691680 |
| EC50 (functional) | = 0.58 uM | Agonist activity for Human PPAR gamma receptor in transcriptional activation assay | ChEMBL. | 10691680 |
| EC50 (binding) | = 0.6 uM | Transactivation activity at Homo sapiens (human) PPARgamma | ChEMBL. | No reference |
| EC50 (functional) | = 0.69 uM | In vitro transcriptional activation of Peroxisome proliferator activated receptor gamma (PPAR) expressed in CV-1 cells | ChEMBL. | 8576907 |
| EC50 (functional) | = 0.69 uM | In vitro transcriptional activation of Peroxisome proliferator activated receptor gamma (PPAR) expressed in CV-1 cells | ChEMBL. | 8576907 |
| EC50 (binding) | = 0.8 uM | Transactivation of human GAL4-fused PPARgamma ligand binding domain transfected in HEK293 cells after 18 hrs by dual luciferase reporter gene assay | ChEMBL. | 23102891 |
| EC50 (functional) | = 0.97 uM | In vitro transactivation using receptor transactivation assay against hPPAR gamma | ChEMBL. | 11831892 |
| EC50 (binding) | = 0.97 uM | In vitro transactivation of human Peroxisome proliferator activated receptor gamma | ChEMBL. | 14584939 |
| EC50 (functional) | = 0.97 uM | In vitro transactivation using receptor transactivation assay against hPPAR gamma | ChEMBL. | 11831892 |
| EC50 (binding) | = 0.97 uM | In vitro transactivation of human Peroxisome proliferator activated receptor gamma | ChEMBL. | 14584939 |
| EC50 (binding) | = 1.6 uM | Displacement of Fluoromone from GST-tagged recombinant human PPARgamma ligand binding domain by LanthaScreen TR-FRET assay | LITERATURE. | 27560282 |
| EC50 (functional) | = 6.68 uM | In vitro transactivation using receptor transactivation assay against hPPAR alpha | ChEMBL. | 11831892 |
| EC50 (binding) | = 6.68 uM | In vitro transactivation of human Peroxisome proliferator activated receptor alpha (hPPARalpha) | ChEMBL. | 14584939 |
| EC50 (functional) | = 6.68 uM | In vitro transactivation using receptor transactivation assay against hPPAR alpha | ChEMBL. | 11831892 |
| EC50 (binding) | = 6.68 uM | In vitro transactivation of human Peroxisome proliferator activated receptor alpha (hPPARalpha) | ChEMBL. | 14584939 |
| EC50 (functional) | = 7.6 uM | Peroxisome proliferator activated receptor gamma agonistic activity in HepG2 cells. | ChEMBL. | 10714503 |
| ED25 (functional) | = 4.6 mg kg-1 day-1 | Effective dose for 25% blood glucose decrease in genetically diabetic KKA mice. | ChEMBL. | 9599241 |
| ED25 (functional) | = 4.6 mg kg-1 day-1 | Effective dose for 25% blood glucose decrease in genetically diabetic KKA mice. | ChEMBL. | 9599241 |
| ED50 (functional) | = 2.6 mg kg-1 | In vivo nonfasting blood glucose in db/db mice after oral treament | ChEMBL. | 14584939 |
| ED50 (functional) | = 2.6 mg kg-1 | In vivo nonfasting blood glucose in db/db mice after oral treament | ChEMBL. | 14584939 |
| ED50 (functional) | = 2.62 mg kg-1 | Nonfasting blood glucose after 7 days treatment in male db/db mice | ChEMBL. | 11831892 |
| ED50 (functional) | = 2.62 mg kg-1 | Nonfasting blood glucose after 7 days treatment in male db/db mice | ChEMBL. | 11831892 |
| ED50 (functional) | = 12 mg kg-1 | Area under blood glucose time curve after oral glucose test in mice | ChEMBL. | 14584939 |
| ED50 (functional) | = 12 mg kg-1 | Area under blood glucose time curve after oral glucose test in mice | ChEMBL. | 14584939 |
| ED50 (functional) | = 15 mg kg-1 | In vivo insulin effect in db/db mice after oral treament | ChEMBL. | 14584939 |
| ED50 (functional) | = 15 mg kg-1 | In vivo insulin effect in db/db mice after oral treament | ChEMBL. | 14584939 |
| ED50 (functional) | = 15.05 mg kg-1 | Nonfasting insulin after 7 days treatment in male db/db mice | ChEMBL. | 11831892 |
| ED50 (functional) | = 15.05 mg kg-1 | Nonfasting insulin after 7 days treatment in male db/db mice | ChEMBL. | 11831892 |
| ED50 (functional) | = 26.74 mg kg-1 | Nonfasting triglycerides after 7 days treatment in male db/db mice | ChEMBL. | 11831892 |
| ED50 (functional) | = 26.74 mg kg-1 | Nonfasting triglycerides after 7 days treatment in male db/db mice | ChEMBL. | 11831892 |
| ED50 (functional) | = 27 mg kg-1 | In vivo nonfasting triglyceride in db/db mice after oral treament | ChEMBL. | 14584939 |
| ED50 (functional) | = 27 mg kg-1 | In vivo nonfasting triglyceride in db/db mice after oral treament | ChEMBL. | 14584939 |
| ED50 (functional) | = 19 mg kg-1 day-1 | Effective dose for 50% blood glucose decrease in genetically diabetic KKA mice. | ChEMBL. | 9599241 |
| ED50 (functional) | = 19 mg kg-1 day-1 | Effective dose for 50% blood glucose decrease in genetically diabetic KKA mice. | ChEMBL. | 9599241 |
| Efficacy (functional) | = 9.17 % | Antidyslipidemic activity in C57BL/Ks db/db mouse assessed as reduction of serum cholesterol level at 10 mg/kg measured on day 10 to 15 relative to vehicle-treated sham control | ChEMBL. | No reference |
| Efficacy (functional) | = 11.1 % | Antidyslipidemic activity in C57BL/Ks db/db mouse assessed as increase in serum HDL-cholesterol level at 10 mg/kg measured on day 10 to 15 relative to vehicle-treated sham control | ChEMBL. | No reference |
| Efficacy (functional) | = 12.6 % | Antidyslipidemic activity in C57BL/Ks db/db mouse assessed as reduction of serum triglyceride level at 10 mg/kg measured on day 10 to 15 relative to vehicle-treated sham control | ChEMBL. | No reference |
| Efficacy (functional) | = 40.8 % | Antihyperglycemic activity in C57BL/Ks db/db mouse assessed as reduction of blood glucose AUC (0 to 120 mins) at 10 mg/kg measured on day 10 by OGTT relative to vehicle-treated sham control | ChEMBL. | No reference |
| Efficacy (functional) | = 46.1 % | Antidiabetic activity in C57BL/Ks db/db mouse assessed as restoration of altered insulin level in serum at 10 mg/kg relative to vehicle-treated sham control | ChEMBL. | No reference |
| Efficacy (functional) | = 52.9 % | Antihyperglycemic activity in C57BL/Ks db/db mouse assessed as reduction of blood glucose AUC (0 to 120 mins) at 10 mg/kg, po measured on day 15 by OGTT relative to vehicle-treated sham control | ChEMBL. | No reference |
| Efficacy (functional) | = 64.7 % | Antidiabetic activity in C57BL/Ks db/db mouse assessed as normalization of fasting blood glucose level at 10 mg/kg relative to vehicle-treated sham control | ChEMBL. | No reference |
| Efficacy (functional) | = 70.3 % | Antidiabetic activity in C57BL/Ks db/db mouse assessed as improvement of HOMA index at 10 mg/kg relative to vehicle-treated sham control | ChEMBL. | No reference |
| Emax (binding) | Transactivation of human PPARdelta expressed in African green monkey COS7 cells at 10 uM incubated overnight by dual-glo luciferase reporter assay | ChEMBL. | 26595749 | |
| Emax (binding) | Transactivation of human PPARalpha expressed in African green monkey COS7 cells incubated overnight by dual-glo luciferase reporter assay relative to GW7647 | ChEMBL. | 26595749 | |
| Emax (binding) | Agonist activity at GAL4-tagged human PPARalpha ligand binding domain expressed in HepG2 cells assessed as transactivation at 5 to 10 uM after 20 hrs by beta-galactosidase reporter gene assay relative to Wy-14643 | ChEMBL. | 22341573 | |
| Emax (binding) | = 80 % | Partial agonist activity at human PPARgamma-LBD/Gal4 DNA binding domain by transactivation assay relative to darglitazone | ChEMBL. | 21557540 |
| Emax (functional) | = 118 % | Agonist activity at PPARgamma assessed as transcriptional activation relative to GI262570 | ChEMBL. | 20219371 |
| F (ADMET) | = 112 % | Oral bioavailability | ChEMBL. | 11831892 |
| Fa (ADMET) | = 83 % | Drug absorption in orally dosed human | ChEMBL. | 25890697 |
| FC (functional) | = 1.37 | In vivo inhibition of PTP1B in skeletal muscle of C57BL/Ks db/db mouse assessed as upregulation of p-IRSI protein expression at 10 mg/kg, po by Western blot analysis relative to vehicle-treated sham control | ChEMBL. | No reference |
| FC (binding) | = 1.64 | Binding affinity to mouse cyclic AMP-dependent transcription factor ATF-2 by chromatographic analysis | ChEMBL. | 22970990 |
| FC (binding) | = 1.88 | Binding affinity to mouse mitochondrial dihydrolipoyl dehydrogenase by chromatographic analysis relative to rosiglitazone | ChEMBL. | 22970990 |
| FC (binding) | = 2.26 | Binding affinity to L-lactate dehydrogenase B chain in Sprague-Dawley rat heart homogenate after 15 mins by chromatographic analysis relative to rosiglitazone | ChEMBL. | 22970990 |
| FC (ADMET) | <= 4 | Full agonist activity at PPARgamma in mouse 3T3L1 preadipocytes assessed as increase in insulin induced adipocyte differentiation by measuring triglyceride accumulation at 1 to 10 uM after 9 days by Oil-Red O staining based assay relative to control | LITERATURE. | 27569195 |
| FC (binding) | = 5.52 | Binding affinity to mouse mitochondrial citrate synthase by chromatographic analysis relative to rosiglitazone | ChEMBL. | 22970990 |
| FC (binding) | = 5.78 | Binding affinity to mitochondrial long-chain specific acyl-CoA dehydrogenase in Sprague-Dawley rat heart homogenate after 15 mins by chromatographic analysis relative to rosiglitazone | ChEMBL. | 22970990 |
| FC (binding) | = 6.16 | Binding affinity to creatine kinase M-type in Sprague-Dawley rat heart homogenate after 15 mins by chromatographic analysis relative to rosiglitazone | ChEMBL. | 22970990 |
| FC (binding) | = 6.2 | Modulation of human PPARgamma-LBD expressed in african green monkey COS7 cells co-transfected with Gal4 assessed as activation of transactivation activity at 1 uM by luciferase assay relative to control | ChEMBL. | 21873070 |
| FC (binding) | = 6.46 | Binding affinity to triosephosphate isomerase in Sprague-Dawley rat heart homogenate after 15 mins by chromatographic analysis relative to rosiglitazone | ChEMBL. | 22970990 |
| FC (binding) | = 6.6 | Agonist activity at human PPARgamma expressed in HEK293 cells assessed as induction of receptor activation at 5 uM incubated for 18 hrs by luciferase reporter gene assay relative to untreated control | ChEMBL. | 25333853 |
| FC (binding) | = 7.8 | Agonist activity at human PPARgamma ligand binding domain expressed in COS-1 cells co-transfected with Gal4 at 10 uM by luciferase reporter gene assay relative to control | ChEMBL. | 21130649 |
| FC (binding) | = 43.1 | Transactivation of PPARgamma (unknown origin) expressed in HEK293A cells at 150 uM after 16 to 18 hrs by luciferase reporter assay relative to control | ChEMBL. | 26974385 |
| fCmax (ADMET) | = 0.029 uM | Unbound Cmax in human plasma | ChEMBL. | 21965623 |
| Fold activation (functional) | = 1.77 | Transcriptional activation of Peroxisome proliferator-activator receptor (PPAR) alpha expressed in HEK 293T cells at 50 uM | ChEMBL. | 11472221 |
| Fold activation (functional) | = 18.4 | Transcriptional activation of Peroxisome proliferator-activator receptor (PPAR) gamma expressed in HEK 293T cells at 1 uM | ChEMBL. | 11472221 |
| Fold activation (binding) | = 1 % | In vitro transactivation of human Peroxisome proliferator activated receptor delta (hPPARdelta) | ChEMBL. | 14584939 |
| Fold activation (binding) | = 1 % | In vitro transactivation of human Peroxisome proliferator activated receptor delta (hPPARdelta) | ChEMBL. | 14584939 |
| Fold activation (binding) | = 4 % | In vitro transactivation of rat Peroxisome proliferator activated receptor alpha | ChEMBL. | 14584939 |
| Fold activation (binding) | = 4 % | In vitro transactivation of rat Peroxisome proliferator activated receptor alpha | ChEMBL. | 14584939 |
| Fold activation (binding) | = 58 % | In vitro transactivation of human Peroxisome proliferator activated receptor alpha (hPPARalpha) | ChEMBL. | 14584939 |
| Fold activation (binding) | = 58 % | In vitro transactivation of human Peroxisome proliferator activated receptor alpha (hPPARalpha) | ChEMBL. | 14584939 |
| Fold activation (binding) | = 91 % | In vitro transactivation of human Peroxisome proliferator activated receptor gamma | ChEMBL. | 14584939 |
| Fold activation (binding) | = 91 % | In vitro transactivation of human Peroxisome proliferator activated receptor gamma | ChEMBL. | 14584939 |
| Glucose level (ADMET) | = 174 mg dl-1 | In vivo blood glucose level was observed in ZDF rats 4 weeks after oral administration (once daily) of 30 mg/kg of compound; (n=6) | ChEMBL. | 15664804 |
| Glucose level (ADMET) | = 432 mg dl-1 | In vivo blood glucose level was observed in db/db mouse 4 weeks after oral administration (once daily) of 100 mg/kg of compound; (n=6) | ChEMBL. | 15664804 |
| IC50 (binding) | DRUGMATRIX: Chemokine CCR4 radioligand binding (ligand: [125I] TARC) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Endothelin ETA radioligand binding (ligand: [125I] Endothelin-1) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Dopamine D1 radioligand binding (ligand: [3H] SCH-23390) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Chemokine CXCR2 (IL-8B) radioligand binding (ligand: [125I] IL-8) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Adenosine A2A radioligand binding (ligand: AB-MECA) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Adenosine A3 radioligand binding (ligand: AB-MECA) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Melanocortin MC3 radioligand binding (ligand: [125I] NDP-alpha-MSH) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Neuropeptide Y Y2 radioligand binding (ligand: [125I] Peptide YY) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Chemokine CCR2B radioligand binding (ligand: [125I] MCP-1) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Chemokine CCR5 radioligand binding (ligand: [125I] MIP-1alpha) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Norepinephrine Transporter radioligand binding (ligand: [125I] RTI-55) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Cyclooxygenase COX-1 enzyme inhibition (substrate: Arachidonic acid) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT4 radioligand binding (ligand: [3H] GR-113808) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Protein Serine/Threonine Phosphatase, PPP3CA (Calcineurin, PP2B) enzyme inhibition (substrate: DiFMUP) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Alpha-1D adrenergic receptor radioligand binding (ligand: prazosin) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: CYP450, 2D6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2B radioligand binding (ligand: [3H] Lysergic acid diethylamide) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Protein Serine/Threonine Kinase PKCalpha enzyme inhibition (substrate: Histone) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Tachykinin NK1 radioligand binding (ligand: [3H] Substance P) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Protease, Caspase 1 enzyme inhibition (substrate: Ac-YVAD-AMC) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Chemokine CXCR1 (IL-8A) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Muscarinic M4 radioligand binding (ligand: [3H] N-Methylscopolamine) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1A radioligand binding (ligand: [3H] 8-OH-DPAT) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Muscarinic M5 radioligand binding (ligand: [3H] N-Methylscopolamine) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Tachykinin NK2 radioligand binding (ligand: [3H] SR-48968) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Peptidase, Angiotensin Converting Enzyme enzyme inhibition (substrate: FAPGG) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Protein Tyrosine Kinase, LCK enzyme inhibition (substrate: Poly(Glu:Tyr)) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT6 radioligand binding (ligand: [3H] Lysergic acid diethylamide) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Sigma1 radioligand binding (ligand: [3H] Haloperidol) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: CYP450, 2E1 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Alpha-2B adrenergic receptor radioligand binding (ligand: Rauwolscine) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr)) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Protease, Cathepsin G enzyme inhibition (substrate: Suc-Ala-Ala-Pro-Phe-AMC) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Adenosine A1 radioligand binding (ligand: DPCPX) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Peptidase, Matrix Metalloprotease-1 (MMP-1) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Calcitonin radioligand binding (ligand: [125I] Calcitonin (salmon)) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Muscarinic M3 radioligand binding (ligand: [3H] N-Methylscopolamine) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Protein Serine/Threonine Kinase, p38alpha enzyme inhibition (substrate: Myelin Basic Protein) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Acetylcholinesterase enzyme inhibition (substrate: acetylthiocholine) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Adrenergic beta3 radioligand binding (ligand: [125I] Cyanopindolol) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Peptidase, ELA2 (Neutrophil Elastase 2) enzyme inhibition (substrate: N-MeOSuc-Ala-Ala-Pro-Val-pNA) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2C radioligand binding (ligand: [3H] Mesulergine) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Melanocortin MC4 radioligand binding (ligand: [125I] NDP-alpha-MSH) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Nitric Oxide Synthase, Inducible (iNOS) enzyme inhibition (substrate: L-Arginine) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Cyclooxygenase COX-2 enzyme inhibition (substrate: Arachidonic acid) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: HMG-CoA Reductase enzyme inhibition (substrate: [14C]HMG-CoA) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Alpha-1B adrenergic receptor radioligand binding (ligand: prazosin) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Thromboxane Synthetase enzyme inhibition (substrate: PGH2) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Insulin radioligand binding (ligand: [125I] Insulin) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: CYP450, 1A2 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Muscarinic M1 radioligand binding (ligand: [3H] N-Methylscopolamine) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Protein Tyrosine Kinase, Fyn enzyme inhibition (substrate: Poly(Glu:Tyr)) | ChEMBL. | No reference | |
| IC50 (binding) | Inhibition of human recombinant sEH using PHOME as substrate preincubated for 30 mins followed by substrate addition measured for 30 mins by fluorescence-based assay | ChEMBL. | 26595749 | |
| IC50 (binding) | DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55) | ChEMBL. | No reference | |
| IC50 (binding) | Inhibition of recombinant soluble epoxide hydrolase using PHOME as substrate after 10 mins by fluorescence assay | ChEMBL. | 23130964 | |
| IC50 (binding) | DRUGMATRIX: Cysteinyl leukotriene receptor 1 radioligand binding (ligand: [3H]LTD4) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Adrenergic beta1 radioligand binding (ligand: [125I] Cyanopindolol) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: CYP450, 2C19 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: CYP450, 2A6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Cannabinoid CB1 radioligand binding (ligand: [3H] SR141716A) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Opiate delta1 (OP1, DOP) radioligand binding (ligand: [3H] Naltrindole) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Protein Serine/Threonine Kinase, ERK2 enzyme inhibition (substrate: Myelin Basic Protein) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Melanocortin MC5 radioligand binding (ligand: [125I] NDP-alpha-MSH) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Leukotriene LTC4 Synthase enzyme inhibition (substrate: LTA4) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Nitric Oxide Synthase, Neuronal (nNOS) radioligand binding (ligand: [3H]L-Arginine) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Bradykinin B2 radioligand binding (ligand: [3H] Bradykinin) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Muscarinic M2 radioligand binding (ligand: [3H] N-Methylscopolamine) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Glucocorticoid radioligand binding (ligand: [3H] Dexamethasone) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1B radioligand binding (ligand: [125I] Cyanopindolol) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Alpha-1A adrenergic receptor radioligand binding (ligand: prazosin) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Estrogen ERalpha radioligand binding (ligand: [3H] Estradiol) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Androgen (Testosterone) AR radioligand binding (ligand: [3H] Mibolerone) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Estrogen ERbeta radioligand binding (ligand: [3H] Estradiol) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Lipoxygenase 15-LO enzyme inhibition (substrate: Linoleic acid) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Platelet Activating Factor (PAF) radioligand binding (ligand: [3H] PAF) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Phosphodiesterase PDE5 enzyme inhibition (substrate: [3H]cGMP + cGMP) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Cholecystokinin CCKA radioligand binding (ligand: [3H] L-364,718) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Neuropeptide Y Y1 radioligand binding (ligand: [125I] Peptide YY) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Progesterone radioligand binding (ligand: [3H] R-5020) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Vasopressin V1A radioligand binding (ligand: [125I] PhenylacetylTyr(Me)PheGlnAsnArgProArgTyr) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Angiotensin AT2 radioligand binding (ligand: [125I] CGP-42112A) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Histamine H2 radioligand binding (ligand: [125I] Aminopotentidine) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Vasoactive Intestinal Peptide VIP1 radioligand binding (ligand: [125I] VIP) | ChEMBL. | No reference | |
| IC50 (binding) | = 720 nM | Agonist activity at PPARgamma (unknown origin) | ChEMBL. | 26048793 |
| IC50 (binding) | = 855 nM | Displacement of fluormone PPAR-green from N-terminal His-tagged human PPARgamma-LBD after 2 hrs by fluorescence polarization assay | ChEMBL. | 21030263 |
| IC50 (binding) | = 0.114 uM | DRUGMATRIX: Carbonic Anhydrase II enzyme inhibition (substrate: 4-Nitrophenyl acetate (4-NPA)) | ChEMBL. | No reference |
| IC50 (binding) | = 0.298 uM | Inhibition of human recombinant MAO-B after 15 mins | ChEMBL. | 20650633 |
| IC50 (binding) | = 0.3 uM | Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake | ChEMBL. | 21965623 |
| IC50 (binding) | = 0.7 uM | Displacement of [3H]rosiglitazone from mouse PPARgamma receptor by scintillation proximation assay | ChEMBL. | 18752947 |
| IC50 (binding) | = 0.7 uM | Displacement of [3H]rosigliatzone from PPARgamma in rat adipocytes | ChEMBL. | 18482837 |
| IC50 (binding) | = 0.8 uM | Displacement of [3H]rosiglitazone from PPAR gamma | ChEMBL. | 17574414 |
| IC50 (binding) | = 0.8 uM | Displacement of [3H]rosiglitazone from PPAR gamma | ChEMBL. | 17574414 |
| IC50 (binding) | = 1 uM | Displacement of [3H]rosiglitazone from rat liver mitochondrial mitoNEET by scintillation counting | ChEMBL. | 20064719 |
| IC50 (binding) | = 2 uM | Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake | ChEMBL. | 21965623 |
| IC50 (binding) | = 7.4 uM | Receptor binding affinity of the compound to human Peroxisome proliferator activated receptor gamma against [3H]-ragalitazar radioligand | ChEMBL. | 12672231 |
| IC50 (binding) | = 7.4 uM | Receptor binding affinity of the compound to human Peroxisome proliferator activated receptor gamma against [3H]-ragalitazar radioligand | ChEMBL. | 12672231 |
| IC50 (binding) | = 8 uM | Inhibition of fluormone binding to human PPARgamma LBD after 2 hrs by competitive fluorescence polarization assay | ChEMBL. | 22424975 |
| IC50 (binding) | = 8.65 uM | Displacement of [3H]rosiglitazone from recombinant human C-terminal His-tagged MitoNEET cytosolic domain (32 to 108 residues) expressed in Escherichia coli BL21 by scintillation proximity assay | LITERATURE. | 27687671 |
| IC50 (binding) | > 10 uM | Receptor binding affinity of the compound to human Peroxisome proliferator activated receptor alpha against [3H]-NNC 0061-4655 radioligand | ChEMBL. | 12672231 |
| IC50 (binding) | > 10 uM | Receptor binding affinity of the compound to human Peroxisome proliferator activated receptor alpha against [3H]-NNC 0061-4655 radioligand | ChEMBL. | 12672231 |
| IC50 (binding) | > 10 uM | SUPPLEMENTARY: Inhibition of Carnitine palmitoyltransferase 1, liver isoform | ChEMBL. | No reference |
| IC50 (binding) | = 13.2 uM | DRUGMATRIX: Aldose Reductase enzyme inhibition (substrate: DL-Glyceraldehyde) | ChEMBL. | No reference |
| IC50 (functional) | = 18.6 uM | Antiinflammatory activity in human THP1 cells assessed as inhibition of PMA-induced MCP-1 secretion incubated for 2 hrs prior to PMA challenge measured after 72 hrs by ELISA | ChEMBL. | 24531227 |
| IC50 (functional) | = 18.84 uM | Antiinflammatory activity in human THP1 cells assessed as inhibition of PMA-induced MCP-1 secretion preincubated for 1 hr prior PMA-challenge measured after 48 hrs by ELISA | ChEMBL. | 23811092 |
| IC50 (binding) | = 35.069 uM | DRUGMATRIX: Monoamine Oxidase MAO-A enzyme inhibition (substrate: Kynuramine) | ChEMBL. | No reference |
| IC50 (functional) | > 50 uM | Antiinflammatory activity in human THP1 cells assessed as inhibition of PMA-induced IL-1beta secretion preincubated for 1 hr prior PMA-challenge measured after 48 hrs by ELISA | ChEMBL. | 23811092 |
| IC50 (binding) | = 79 uM | Inhibition of C-terminal His6-tagged Francisella tularensis SCHU S4 FabI expressed in Escherichia coli BL21 (DE3) using CrCoA as substrate assessed as oxidation of NADH to NAD+ by fluorescence assay | ChEMBL. | 23815100 |
| IC50 (binding) | > 100 uM | SUPPLEMENTARY: Inhibition of Carnitine palmitoyltransferase 1, muscle isoform | ChEMBL. | No reference |
| IC50 (binding) | > 100 uM | SUPPLEMENTARY: Inhibition of Carnitine palmitoyltransferase 2 | ChEMBL. | No reference |
| IC50 (binding) | > 100 uM | SUPPLEMENTARY | SUPPLEMENTARY. | No reference |
| IC50 (binding) | = 220 uM | Inhibition of PTP1B | ChEMBL. | 19783142 |
| Inhibition (ADMET) | Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins | ChEMBL. | 22931300 | |
| Inhibition (ADMET) | Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins | ChEMBL. | 22931300 | |
| Inhibition (ADMET) | Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins | ChEMBL. | 22931300 | |
| Inhibition (ADMET) | Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins | ChEMBL. | 22931300 | |
| Inhibition (ADMET) | Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins | ChEMBL. | 22931300 | |
| Inhibition (binding) | Inhibition of human MAOA expressed in Pichia pastoris at 100 uM | ChEMBL. | 22282722 | |
| Inhibition (ADMET) | Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins | ChEMBL. | 22931300 | |
| Inhibition (binding) | Inhibition of rat MAOA expressed in Pichia pastoris at 100 uM | ChEMBL. | 22282722 | |
| Inhibition (ADMET) | = -9.9 % | Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting | ChEMBL. | 22541068 |
| Inhibition (ADMET) | = 5.6 % | Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting | ChEMBL. | 22541068 |
| Inhibition (ADMET) | < 10 % | Time dependent inhibition of CYP1A2 (unknown origin) at 100 uM by LC/MS system | ChEMBL. | 21467212 |
| Inhibition (ADMET) | < 10 % | Time dependent inhibition of CYP2C9 (unknown origin) at 100 uM by LC/MS system | ChEMBL. | 21467212 |
| Inhibition (ADMET) | < 10 % | Time dependent inhibition of CYP2C8 (unknown origin) at 30 uM by LC/MS system | ChEMBL. | 21467212 |
| Inhibition (ADMET) | < 10 % | Time dependent inhibition of CYP2C19 in human liver microsomes at 100 uM by LC/MS system | ChEMBL. | 21467212 |
| Inhibition (ADMET) | < 10 % | Time dependent inhibition of CYP2D6 (unknown origin) at 100 uM by LC/MS system | ChEMBL. | 21467212 |
| Inhibition (functional) | = 10 % | Antidiabetic effect in db/db mouse assessed as increase in HDL cholesterol level at 30 mg/kg/day, po administered daily for 14 days | ChEMBL. | 21377875 |
| Inhibition (ADMET) | = 21.9 % | Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting | ChEMBL. | 22541068 |
| Inhibition (functional) | > 25 % | Hypoglycemic effect in eight week old female db/db mouse assessed as reduction in blood glucose level at 30 mg/kg, intragastric for 1 week | ChEMBL. | 25724827 |
| Inhibition (ADMET) | = 38 % | Time dependent inhibition of CYP2B6 (unknown origin) at 100 uM by LC/MS system | ChEMBL. | 21467212 |
| Inhibition (functional) | = 46 % | Antidiabetic effect in db/db mouse assessed as reduction in plasma glucose level at 30 mg/kg/day, po administered daily for 14 days | ChEMBL. | 21377875 |
| Inhibition (ADMET) | = 61 % | Time dependent inhibition of CYP3A4 (unknown origin) at 100 uM by LC/MS system | ChEMBL. | 21467212 |
| Inhibition (functional) | = 65 % | TP_TRANSPORTER: inhibition of estrone-3-sulfate uptake (Estrone-3-sulfate: 9.2 nM) by Pioglitazone at a concentration of 10uM in OATP8-expressing Xenopus oocytes | ChEMBL. | 14977862 |
| Inhibition (binding) | = 67.5 % | Displacement of Fluoromone from GST-tagged recombinant human PPARgamma ligand binding domain at 10 uM by LanthaScreen TR-FRET assay relative to control | LITERATURE. | 27560282 |
| Inhibition (functional) | = 69 % | Antidiabetic effect in db/db mouse assessed as reduction in plasma triglyceride level at 30 mg/kg/day, po administered daily for 14 days | ChEMBL. | 21377875 |
| Inhibition (functional) | = 70 % | TP_TRANSPORTER: inhibition of estrone-3-sulfate uptake (Estrone-3-sulfate: 9.2 nM) by Pioglitazone at a concentration of 10uM in OATP-C-expressing Xenopus oocytes | ChEMBL. | 14977862 |
| Ki (binding) | DRUGMATRIX: Muscarinic M2 radioligand binding (ligand: [3H] N-Methylscopolamine) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Protease, Cathepsin G enzyme inhibition (substrate: Suc-Ala-Ala-Pro-Phe-AMC) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Glucocorticoid radioligand binding (ligand: [3H] Dexamethasone) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Bradykinin B2 radioligand binding (ligand: [3H] Bradykinin) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Chemokine CXCR2 (IL-8B) radioligand binding (ligand: [125I] IL-8) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr)) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Calcitonin radioligand binding (ligand: [125I] Calcitonin (salmon)) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Cholecystokinin CCKA radioligand binding (ligand: [3H] L-364,718) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Acetylcholinesterase enzyme inhibition (substrate: acetylthiocholine) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: CYP450, 2D6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Platelet Activating Factor (PAF) radioligand binding (ligand: [3H] PAF) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Androgen (Testosterone) AR radioligand binding (ligand: [3H] Mibolerone) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Thromboxane Synthetase enzyme inhibition (substrate: PGH2) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Opiate delta1 (OP1, DOP) radioligand binding (ligand: [3H] Naltrindole) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Muscarinic M4 radioligand binding (ligand: [3H] N-Methylscopolamine) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Vasoactive Intestinal Peptide VIP1 radioligand binding (ligand: [125I] VIP) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT4 radioligand binding (ligand: [3H] GR-113808) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Sigma1 radioligand binding (ligand: [3H] Haloperidol) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Tachykinin NK1 radioligand binding (ligand: [3H] Substance P) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: CYP450, 2E1 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Peptidase, Angiotensin Converting Enzyme enzyme inhibition (substrate: FAPGG) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: CYP450, 2C19 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Melanocortin MC3 radioligand binding (ligand: [125I] NDP-alpha-MSH) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Cysteinyl leukotriene receptor 1 radioligand binding (ligand: [3H]LTD4) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Melanocortin MC4 radioligand binding (ligand: [125I] NDP-alpha-MSH) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Alpha-1D adrenergic receptor radioligand binding (ligand: prazosin) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Insulin radioligand binding (ligand: [125I] Insulin) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Vasopressin V1A radioligand binding (ligand: [125I] PhenylacetylTyr(Me)PheGlnAsnArgProArgTyr) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Endothelin ETA radioligand binding (ligand: [125I] Endothelin-1) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Estrogen ERalpha radioligand binding (ligand: [3H] Estradiol) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Adenosine A2A radioligand binding (ligand: AB-MECA) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Adenosine A3 radioligand binding (ligand: AB-MECA) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Chemokine CCR4 radioligand binding (ligand: [125I] TARC) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Progesterone radioligand binding (ligand: [3H] R-5020) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Adrenergic beta1 radioligand binding (ligand: [125I] Cyanopindolol) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Monoamine Oxidase MAO-A enzyme inhibition (substrate: Kynuramine) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Protease, Caspase 1 enzyme inhibition (substrate: Ac-YVAD-AMC) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Cannabinoid CB1 radioligand binding (ligand: [3H] SR141716A) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Neuropeptide Y Y1 radioligand binding (ligand: [125I] Peptide YY) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: CYP450, 1A2 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT6 radioligand binding (ligand: [3H] Lysergic acid diethylamide) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Lipoxygenase 15-LO enzyme inhibition (substrate: Linoleic acid) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Protein Tyrosine Kinase, ERBB2 (HER2) enzyme inhibition (substrate: Poly(Glu:Tyr)) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Aldose Reductase enzyme inhibition (substrate: DL-Glyceraldehyde) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Alpha-1B adrenergic receptor radioligand binding (ligand: prazosin) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Muscarinic M1 radioligand binding (ligand: [3H] N-Methylscopolamine) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Chemokine CCR5 radioligand binding (ligand: [125I] MIP-1alpha) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Peptidase, Matrix Metalloprotease-1 (MMP-1) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Neuropeptide Y Y2 radioligand binding (ligand: [125I] Peptide YY) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: HMG-CoA Reductase enzyme inhibition (substrate: [14C]HMG-CoA) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Estrogen ERbeta radioligand binding (ligand: [3H] Estradiol) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1B radioligand binding (ligand: [125I] Cyanopindolol) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Cyclooxygenase COX-1 enzyme inhibition (substrate: Arachidonic acid) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Chemokine CCR2B radioligand binding (ligand: [125I] MCP-1) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2B radioligand binding (ligand: [3H] Lysergic acid diethylamide) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Protein Tyrosine Kinase, LCK enzyme inhibition (substrate: Poly(Glu:Tyr)) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Protein Serine/Threonine Kinase, p38alpha enzyme inhibition (substrate: Myelin Basic Protein) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Alpha-1A adrenergic receptor radioligand binding (ligand: prazosin) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Histamine H2 radioligand binding (ligand: [125I] Aminopotentidine) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Muscarinic M3 radioligand binding (ligand: [3H] N-Methylscopolamine) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1A radioligand binding (ligand: [3H] 8-OH-DPAT) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Protein Serine/Threonine Kinase, ERK2 enzyme inhibition (substrate: Myelin Basic Protein) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Norepinephrine Transporter radioligand binding (ligand: [125I] RTI-55) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Chemokine CXCR1 (IL-8A) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Carbonic Anhydrase II enzyme inhibition (substrate: 4-Nitrophenyl acetate (4-NPA)) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Nitric Oxide Synthase, Inducible (iNOS) enzyme inhibition (substrate: L-Arginine) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Phosphodiesterase PDE5 enzyme inhibition (substrate: [3H]cGMP + cGMP) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Leukotriene LTC4 Synthase enzyme inhibition (substrate: LTA4) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Adenosine A1 radioligand binding (ligand: DPCPX) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Cyclooxygenase COX-2 enzyme inhibition (substrate: Arachidonic acid) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Protein Serine/Threonine Phosphatase, PPP3CA (Calcineurin, PP2B) enzyme inhibition (substrate: DiFMUP) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Protein Serine/Threonine Kinase PKCalpha enzyme inhibition (substrate: Histone) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Tachykinin NK2 radioligand binding (ligand: [3H] SR-48968) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Alpha-2B adrenergic receptor radioligand binding (ligand: Rauwolscine) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Adrenergic beta3 radioligand binding (ligand: [125I] Cyanopindolol) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Muscarinic M5 radioligand binding (ligand: [3H] N-Methylscopolamine) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Peptidase, ELA2 (Neutrophil Elastase 2) enzyme inhibition (substrate: N-MeOSuc-Ala-Ala-Pro-Val-pNA) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Melanocortin MC5 radioligand binding (ligand: [125I] NDP-alpha-MSH) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Protein Tyrosine Kinase, Fyn enzyme inhibition (substrate: Poly(Glu:Tyr)) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Nitric Oxide Synthase, Neuronal (nNOS) radioligand binding (ligand: [3H]L-Arginine) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Angiotensin AT2 radioligand binding (ligand: [125I] CGP-42112A) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Dopamine D1 radioligand binding (ligand: [3H] SCH-23390) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2C radioligand binding (ligand: [3H] Mesulergine) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: CYP450, 2A6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin) | ChEMBL. | No reference | |
| Ki (binding) | = -5.91 | In vitro binding to peroxisome proliferator activated receptor gamma (PPAR gamma) using [3H]-BRL 49653 as radioligand in scintillation proximity assay (SPA) | ChEMBL. | 9836620 |
| Ki (binding) | = -5.91 | Binding affinity against Peroxisome proliferator activated receptor gamma (PPAR gamma) | ChEMBL. | 10612594 |
| Ki (binding) | nM | Binding affinity against Peroxisome Proliferator activated receptor alpha (PPAR alpha); Not active | ChEMBL. | 10612594 |
| Ki (binding) | nM | Binding affinity against Peroxisome proliferator activated receptor delta (PPAR delta); Not active | ChEMBL. | 10612594 |
| Ki (binding) | 0 nM | Binding affinity against Peroxisome Proliferator activated receptor alpha (PPAR alpha); Not active | ChEMBL. | 10612594 |
| Ki (binding) | 0 nM | Binding affinity against Peroxisome proliferator activated receptor delta (PPAR delta); Not active | ChEMBL. | 10612594 |
| Ki (binding) | = 199.4 nM | Inhibition of human recombinant soluble MAO-B expressed in Pichia pastoris incubated for 30 mins prior to substrate addition measured after 60 mins by MAO-Glo assay | ChEMBL. | 25600407 |
| Ki (binding) | = 270.8 nM | Inhibition of human recombinant microsomal MAO-B expressed in Pichia pastoris incubated for 30 mins prior to substrate addition measured after 60 mins by MAO-Glo assay | ChEMBL. | 25600407 |
| Ki (binding) | = 630 nM | Binding affinity to human Peroxisome proliferator activated receptor gamma using scintillation proximity assay | ChEMBL. | 11720854 |
| Ki (binding) | = 630 nM | Binding affinity to human Peroxisome proliferator activated receptor gamma using scintillation proximity assay | ChEMBL. | 11720854 |
| Ki (binding) | = 0.37 uM | Displacement of [3H]rosiglitazone from recombinant human C-terminal His-tagged MitoNEET cytosolic domain (32 to 108 residues) expressed in Escherichia coli BL21 by Cheng-Prusoff analysis | LITERATURE. | 27687671 |
| Ki (binding) | = 0.5 uM | Competitive inhibition of human MAOB expressed in Pichia pastoris | ChEMBL. | 22282722 |
| Ki (binding) | = 2.1 uM | Competitive inhibition of rat MAOB expressed in Pichia pastoris | ChEMBL. | 22282722 |
| Log EC50 (functional) | = 6.23 | Activation of peroxisome proliferator activated receptor gamma measured by induction of 50% of maximum alkaline phosphatase activity, transfection assay in CV-1 cells | ChEMBL. | 9836620 |
| Log EC50 (functional) | = 6.23 | Transcriptional activation of peroxisome proliferator activated receptor gamma | ChEMBL. | 10612594 |
| Log Ki (binding) | = 5.91 | In vitro binding to peroxisome proliferator activated receptor gamma (PPAR gamma) using [3H]-BRL 49653 as radioligand in scintillation proximity assay (SPA) | ChEMBL. | 9836620 |
| Log Ki (binding) | = 5.91 | Binding affinity against Peroxisome proliferator activated receptor gamma (PPAR gamma) | ChEMBL. | 10612594 |
| Max (functional) | = 1 % | Fold activation relative to maximum activation obtained with carbacyclin | ChEMBL. | 11831892 |
| Max (functional) | = 1 % | Fold activation relative to maximum activation obtained with carbacyclin | ChEMBL. | 11831892 |
| Max (functional) | = 57.8 % | Fold activation relative to maximum hPPAR alpha activation obtained with WY14643 | ChEMBL. | 11831892 |
| Max (functional) | = 57.8 % | Fold activation relative to maximum hPPAR alpha activation obtained with WY14643 | ChEMBL. | 11831892 |
| Max (functional) | = 90.8 % | Fold activation relative to maximum activation obtained with rosiglitazone | ChEMBL. | 11831892 |
| Max (functional) | = 90.8 % | Fold activation relative to maximum activation obtained with rosiglitazone | ChEMBL. | 11831892 |
| Max reduction (functional) | = 21 % | Maximum achieved triglycerides reduction relative to vehicle treated control group | ChEMBL. | 11831892 |
| Max reduction (functional) | = 21 % | In vivo nonfasting triglyceride in db/db mice after oral treament | ChEMBL. | 14584939 |
| Max reduction (functional) | = 21 % | Maximum achieved triglycerides reduction relative to vehicle treated control group | ChEMBL. | 11831892 |
| Max reduction (functional) | = 21 % | In vivo nonfasting triglyceride in db/db mice after oral treament | ChEMBL. | 14584939 |
| Max reduction (functional) | = 39 % | Maximum achieved blood glucose reduction relative to vehicle treated control group | ChEMBL. | 11831892 |
| Max reduction (functional) | = 39 % | Area under blood glucose time curve after oral glucose test in mice | ChEMBL. | 14584939 |
| Max reduction (functional) | = 39 % | Maximum achieved blood glucose reduction relative to vehicle treated control group | ChEMBL. | 11831892 |
| Max reduction (functional) | = 39 % | Area under blood glucose time curve after oral glucose test in mice | ChEMBL. | 14584939 |
| Max reduction (functional) | = 53 % | Maximum achieved blood glucose reduction relative to vehicle treated control group | ChEMBL. | 11831892 |
| Max reduction (functional) | = 53 % | In vivo nonfasting blood glucose in db/db mice after oral treament | ChEMBL. | 14584939 |
| Max reduction (functional) | = 53 % | Maximum achieved blood glucose reduction relative to vehicle treated control group | ChEMBL. | 11831892 |
| Max reduction (functional) | = 53 % | In vivo nonfasting blood glucose in db/db mice after oral treament | ChEMBL. | 14584939 |
| Max reduction (functional) | = 54 % | Maximum achieved insulin reduction relative to vehicle treated control group | ChEMBL. | 11831892 |
| Max reduction (functional) | = 54 % | In vivo insulin effect in db/db mice after oral treament | ChEMBL. | 14584939 |
| Max reduction (functional) | = 54 % | Maximum achieved insulin reduction relative to vehicle treated control group | ChEMBL. | 11831892 |
| Max reduction (functional) | = 54 % | In vivo insulin effect in db/db mice after oral treament | ChEMBL. | 14584939 |
| MED (functional) | = 300 uM kg-1 | Minimum effective dose required for significant reduction in blood glucose in ob/ob mice | ChEMBL. | 8576907 |
| MED (functional) | = 300 uM kg-1 | Minimum effective dose required for significant reduction in blood glucose in ob/ob mice | ChEMBL. | 8576907 |
| MED (functional) | = 200 uM.kg/diet | Minimum effective dose for anti-hyperglycaemic activity was determined in C57B1/6 ob/ob obese mouse | ChEMBL. | No reference |
| MED (functional) | = 200 uM.kg/diet | Minimum effective dose for anti-hyperglycaemic activity was determined in C57B1/6 ob/ob obese mouse | ChEMBL. | No reference |
| PB (ADMET) | = 353 pmol | Covalent binding in human liver microsomes measured per mg of protein using radiolabelled compound at 10 uM after 1 hr incubation by liquid scintillation counting | ChEMBL. | 21467212 |
| Potency (functional) | 1.7291 uM | PubChem BioAssay. qHTS for small molecule inhibitors of Yes1 kinase: Primary Screen. (Class of assay: confirmatory) | ChEMBL. | No reference |
| Potency (functional) | 2.5119 uM | PubChem BioAssay. qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1). (Class of assay: confirmatory) | ChEMBL. | No reference |
| Potency (functional) | = 15.8489 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1). (Class of assay: confirmatory) [Related pubchem assays: 1030 (qHTS Validation Assay for Inhibitors of aldehyde dehydrogenase 1 (ALDH1A1))] | ChEMBL. | No reference |
| Rate of decrease (functional) | = 41 % | IIn vivo decrease in insulin in obese mice(ob/ob) at 10 mg/kg/day peroral administration for 2 weeks | ChEMBL. | 10098657 |
| Rate of decrease (functional) | = 41 % | IIn vivo decrease in insulin in obese mice(ob/ob) at 10 mg/kg/day peroral administration for 2 weeks | ChEMBL. | 10098657 |
| Rate of decrease (functional) | = 43 % | In vivo decrease in insulin in obese mice(ob/ob) at 3 mg/kg/day peroral administration for 2 weeks | ChEMBL. | 10098657 |
| Rate of decrease (functional) | = 43 % | In vivo decrease in insulin in obese mice(ob/ob) at 3 mg/kg/day peroral administration for 2 weeks | ChEMBL. | 10098657 |
| Rate of decrease (functional) | = 64 % | In vivo decrease in glucose in obese mice(ob/ob) at 3 mg/kg/day peroral administration for 2 weeks | ChEMBL. | 10098657 |
| Rate of decrease (functional) | = 64 % | In vivo decrease in glucose in obese mice(ob/ob) at 3 mg/kg/day peroral administration for 2 weeks | ChEMBL. | 10098657 |
| Rate of decrease (functional) | = 75 % | In vivo decrease in glucose in obese mice(ob/ob) at 10 mg/kg/day peroral administration for 2 weeks | ChEMBL. | 10098657 |
| Rate of decrease (functional) | = 75 % | In vivo decrease in glucose in obese mice(ob/ob) at 10 mg/kg/day peroral administration for 2 weeks | ChEMBL. | 10098657 |
| Rate of decrease (functional) | = 85 % | In vivo decrease in triglyceride in obese mice(ob/ob) by 3 mg/kg/day peroral administration for 2 weeks | ChEMBL. | 10098657 |
| Rate of decrease (functional) | = 85 % | In vivo decrease in triglyceride in obese mice(ob/ob) by 3 mg/kg/day peroral administration for 2 weeks | ChEMBL. | 10098657 |
| Rate of decrease (functional) | = 99 % | In vivo decrease in glucose in obese mice(ob/ob) by 10 mg/kg/day peroral administration for 2 weeks | ChEMBL. | 10098657 |
| Rate of decrease (functional) | = 99 % | In vivo decrease in glucose in obese mice(ob/ob) by 10 mg/kg/day peroral administration for 2 weeks | ChEMBL. | 10098657 |
| Reduction (functional) | 0 % | Percent reduction in area under glucose tolerance curve (AUC) was determined at 100 micromol/kg dose of diet in mice; IA = No significant activity | ChEMBL. | 7966158 |
| Reduction (functional) | = 35 % | Percent reduction in area under glucose tolerance curve at 300 uM/kg dose in diet of mice. | ChEMBL. | 7966158 |
| Reduction (functional) | = 35 % | Percent reduction in area under glucose tolerance curve at 300 uM/kg dose in diet of mice. | ChEMBL. | 7966158 |
| Reduction (functional) | = 62 % | Percent reduction in area under glucose tolerance curve (AUC) was determined at 1000 micromol/kg dose of diet in mice | ChEMBL. | 7966158 |
| Reduction (functional) | = 62 % | Percent reduction in area under glucose tolerance curve (AUC) was determined at 1000 micromol/kg dose of diet in mice | ChEMBL. | 7966158 |
| Reduction (functional) | = 63 % | Percent reduction in area under glucose tolerance curve (AUC) was determined at 3000 micromol/kg dose of diet in mice | ChEMBL. | 7966158 |
| Reduction (functional) | = 63 % | Percent reduction in area under glucose tolerance curve (AUC) was determined at 3000 micromol/kg dose of diet in mice | ChEMBL. | 7966158 |
| RLU (functional) | = 2.1 | Agonist activity at human PPARgamma expressed in human HEK293 cells assessed as SHP promoter transactivation at 100 nM by luciferase reporter gene assay relative to vehicle-treated control | ChEMBL. | 22424975 |
| RLU (functional) | = 2.2 | Agonist activity at human PPARgamma expressed in human HEK293 cells at 100 nM by luciferase reporter gene assay relative to vehicle-treated control | ChEMBL. | 22424975 |
| RLU (functional) | = 2.8 | Agonist activity at human PPARgamma expressed in human HEK293 cells assessed as ABCA1 promoter transactivation at 100 nM by luciferase reporter gene assay relative to vehicle-treated control | ChEMBL. | 22424975 |
| T/C (functional) | = 0.49 | Compound was evaluated for Antihyperglycemic activity in KKAy mice, glucose level for the treated group (T) over the anti-hyperglycaemic activity | ChEMBL. | 8978836 |
| T/C (functional) | = 0.49 | Compound was evaluated for Antihyperglycemic activity in KKAy mice, glucose level for the treated group (T) over the anti-hyperglycaemic activity | ChEMBL. | 8978836 |
| T1/2 (ADMET) | = 228 min | Oral half life of the compound was reported | ChEMBL. | 11831892 |
| Triglyceride level (ADMET) | = 73 mg dl-1 | In vivo triglyceride level was observed in db/db mouse 4 weeks after oral administration (once daily) of 100 mg/kg of compound; (n=6) | ChEMBL. | 15664804 |
| Triglyceride level (ADMET) | = 109 mg dl-1 | In vivo triglyceride level was observed in ZDF rats 4 weeks after oral administration (once daily) of 30 mg/kg of compound; (n=6) | ChEMBL. | 15664804 |
| Vss (ADMET) | = 0.22 l kg-1 | Volume of distribution during steady state | ChEMBL. | 11831892 |
Phenotypes
Whole-cell/tissue/organism interactions
| Species name | Source | Reference | Is orphan |
|---|---|---|---|
| Mus musculus | ChEMBL23 | 9599241 | |
| Homo sapiens | ChEMBL23 | 23811092 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
Annotated phenotypes:
We have no manually annotated phenotypes for this drug.
What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by
drugs, or by genetic manipulation of cells (e.g. gene knockouts or
knockdowns) is manually curated from the literature. These
descriptions help to describe the potential of the target for drug
development. If no information is available for this gene or if the
information is incomplete, this may mean that i) the papers
containing this information either appeared after the curation
effort for this organism was carried out or they were inadvertently
missed by curators; or that ii) the curation effort for this
organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.
External resources for this compound
Bibliographic References
56 literature references were collected for this gene.
If you have references for this compound, please enter them in a user comment (below) or Contact us.